

**DETRIMENTAL EFFECTS OF DIETARY SUGAR ON HUMAN HEALTH: A DECADE OF EVIDENCE FROM 2015 ONWARD****Md. Al Amin<sup>1,2\*</sup>, Md. Rezwana Hossain<sup>2</sup>, Md. Ismail Kabir<sup>1</sup>, Moazzema Binta Bashar<sup>3</sup>**<sup>1</sup>Department of Pharmacy, University of Information Technology and Sciences (UITS), Dhaka 1212, Bangladesh.<sup>2</sup>Department of Pharmacy, University of Rajshahi, Rajshahi-6205, Bangladesh.<sup>3</sup>State University of Bangladesh, Dhaka-1461, Bangladesh.

Article Received on 15 Feb. 2026,  
Article Revised on 05 March. 2026,  
Article Published on 16 March 2026,

<https://doi.org/10.5281/zenodo.19044530>

**\*Corresponding Author****Md. Al Amin**

Department of Pharmacy, University of Information Technology and Sciences (UITS), Dhaka 1212, Bangladesh.



**How to cite this Article:** Md. Al Amin<sup>1,2\*</sup>, Md. Rezwana Hossain<sup>2</sup>, Md. Ismail Kabir<sup>1</sup>, Moazzema Binta Bashar<sup>3</sup> (2026). Detrimental Effects Of Dietary Sugar On Human Health: A Decade Of Evidence From 2015 Onward. World Journal of Pharmaceutical Research, 15(6), 439-488.

This work is licensed under Creative Commons Attribution 4.0 International license.

**ABSTRACT**

Excessive dietary sugar intake has emerged as a major contributor to the global burden of non-communicable diseases over the past decade. While naturally occurring, sugars are present in whole foods, high consumption of added sugars, particularly from sugar-sweetened beverages and ultra-processed products, has been strongly associated with adverse metabolic and systemic effects. This review synthesizes evidence published between 2015 and 2025 on the detrimental impact of sugar on human health. Mechanistically, chronic high sugar intake promotes hyperglycemia, insulin resistance, hepatic de novo lipogenesis, uric acid production, oxidative stress, and formation of advanced glycation end products. These processes contribute to obesity, type 2 diabetes mellitus, non-alcoholic fatty liver disease, and cardiovascular disorders. Emerging data also suggest associations with cognitive

impairment, renal dysfunction, gut microbiota dysbiosis, reproductive hormonal imbalance, and increased cancer risk, largely mediated through chronic inflammation and metabolic disruption. Although observational and interventional studies vary in design and quality, the overall body of evidence supports a consistent link between excessive added sugar consumption and multi-organ dysfunction. Public health strategies aimed at reducing added sugar intake may therefore play a critical role in preventing metabolic and chronic diseases.

Continued research is needed to clarify dose–response relationships and long-term outcomes across diverse populations.

**KEYWORDS:** Added sugar; Insulin resistance; Non-alcoholic fatty liver disease; Oxidative stress; Cardiovascular disease; Chronic inflammation.

## INTRODUCTION

Dietary sugar has become one of the most pervasive components of the modern diet and a leading factor in the global rise of non-communicable diseases. Sugar is present not only in obvious sources such as sweets and sugary drinks but also in a wide range of processed foods.<sup>[1]</sup> While sugars naturally occur in fruits and dairy, the primary public health concern is added or free sugars, those included during food processing, preparation, or at the table.<sup>[2]</sup> The World Health Organization recommends that free sugars make up less than 10 percent of total daily energy intake, and ideally less than 5 percent for additional health benefits.<sup>[3]</sup> Despite these guidelines, many populations worldwide exceed these limits substantially.

Global sugar consumption, measured both in total volume and per capita intake, continues to rise. Projections from the Food and Agriculture Organization and the Organization for Economic Co-operation and Development indicate that global sugar demand will grow by more than one percent per year over the next decade, reaching nearly 200-202 million tons by the early 2030s.<sup>[4]</sup> In many regions, population growth and rising incomes support this increase, especially in South and Southeast Asia and parts of Africa where per capita sugar intake is currently lower but on the rise.<sup>[4]</sup>

Excessive sugar intake has a direct link to a range of adverse health outcomes. The global burden of obesity has reached epidemic proportions, driven in part by high-calorie, low-nutrient diets rich in added sugars.<sup>[5]</sup> Although the exact contribution of sugar to obesity varies by region and individual dietary patterns, the trend is clear: as sugar consumption increases, so do rates of overweight and obesity.<sup>[6]</sup> The rise in obesity contributes to a parallel rise in type 2 diabetes and cardiovascular diseases.<sup>[7]</sup> These diseases are among the leading causes of death worldwide, responsible for more than 40 million deaths annually, or roughly 65 percent of all mortality.<sup>[8]</sup>

A growing body of evidence quantifies the impact of sugar-sweetened beverages (SSBs) — one of the most concentrated sources of added sugars in many diets — on global health.<sup>[9]</sup> A

recent analysis across 184 countries estimated that in 2020, SSB consumption was responsible for approximately 2.2 million new cases of type 2 diabetes and 1.2 million new cases of cardiovascular disease, and these figures represent nearly 10 percent of all new diabetes cases and more than 3 percent of new cardiovascular cases worldwide.<sup>[10]</sup> In terms of disability and mortality, sugar-related diseases accounted for millions of disability-adjusted life years (DALYs) and hundreds of thousands of deaths, underlining the extensive human and economic costs tied to high sugar intake.<sup>[11]</sup>

Dental health is also profoundly affected by sugar consumption. Tooth decay remains one of the most common preventable conditions globally, affecting an estimated 2.5 billion people at some point in their lives.<sup>[12]</sup> Free sugars are the primary dietary risk factor for dental caries, and evidence suggests that limiting sugar intake can significantly reduce the prevalence of this condition throughout the life course.<sup>[13]</sup>

Across regions, patterns of consumption and disease burden vary. In high-income countries and Latin America, SSB consumption and its attributable disease burden are particularly high, while lower but increasing consumption in parts of Asia and Africa suggests an emerging public health challenge.<sup>[14]</sup> Many governments are responding with policy measures such as taxes on sugary drinks, advertising restrictions, and reformulation targets for processed foods — interventions that have shown promise in some settings.<sup>[15]</sup> Recent news shows that several countries, including China, are considering or implementing fiscal policies aimed at reducing sugar intake to curb obesity and related diseases.<sup>[16]</sup>

Despite some signs of slowed growth in sugar consumption in parts of the world, largely due to public health efforts and shifting consumer preferences, the overall global trend remains upward. Without intensified interventions and public awareness, the continued rise in added sugar intake will likely drive further increases in metabolic diseases and healthcare costs worldwide.

## METHODOLOGY

This review was conducted to synthesize evidence published over the ten-year period from 2015 to 2025 regarding the detrimental effects of excessive sugar consumption on human health. Although structured as a narrative review, a systematic search strategy was applied to enhance methodological rigor and transparency.

## Literature Search Strategy

A comprehensive literature search was conducted using multiple electronic databases, including PubMed, Scopus, Web of Science, Cochrane Library, ScienceDirect, and Google Scholar, to ensure broad coverage of biomedical, clinical, and public health research. The search was limited to studies published between January 2015 and December 2025 and restricted to articles available in English.

The following keywords and combinations were used: “added sugar”, “dietary sugar”, “fructose metabolism”, “glucose metabolism”, “insulin resistance”, “non-alcoholic fatty liver disease”, “cardiovascular disease”, “oxidative stress”, “inflammation”, “cancer risk”, and “metabolic syndrome” were applied to refine the search strategy.

## 1. Types and Metabolism of Sugar

Dietary sugars are primarily consumed as monosaccharides, such as glucose and fructose, or as disaccharides like sucrose, which is composed of one glucose and one fructose molecule. Although both glucose and fructose provide energy, their metabolic pathways and physiological consequences differ significantly. **Figure 1** illustrates the distinct metabolic fates of glucose and fructose following ingestion and their differential effects on energy homeostasis and disease pathogenesis.

### 1.1 Glucose Metabolism: Glycolysis and Insulin Regulation

Glucose is the principal energy substrate for most tissues. After ingestion, it is absorbed from the intestine into the bloodstream, raising plasma glucose levels. This increase stimulates pancreatic  $\beta$ -cells to release insulin.<sup>[17]</sup> Insulin facilitates glucose uptake into insulin-sensitive tissues such as skeletal muscle and adipose tissue through translocation of GLUT4 transporters to the cell membrane.<sup>[18]</sup>

Once inside the cell, glucose undergoes glycolysis, a cytoplasmic pathway that converts glucose into pyruvate while generating ATP and reducing equivalents (NADH).<sup>[19]</sup> Pyruvate subsequently enters the mitochondria and is converted into acetyl-CoA, which enters the tricarboxylic acid cycle for further energy production.<sup>[20]</sup> In conditions of excess glucose availability, insulin promotes glycogenesis in the liver and muscle and stimulates lipogenesis when glycogen stores are saturated.<sup>[21,22]</sup>

Chronic high glucose intake leads to persistent hyperglycemia and hyperinsulinemia. Over time, this may cause insulin resistance, characterized by reduced responsiveness of peripheral tissues to insulin.<sup>[23]</sup> Compensatory hyperinsulinemia further disrupts metabolic homeostasis and contributes to obesity, type 2 diabetes mellitus, and cardiovascular complications.<sup>[24]</sup>

### 1.2 Fructose Metabolism in the Liver

Fructose metabolism differs fundamentally from glucose metabolism. Unlike glucose, fructose uptake is largely insulin-independent.<sup>[25]</sup> After absorption, fructose is transported to the liver, where it is phosphorylated by fructokinase to form fructose-1-phosphate. This pathway bypasses phosphofructokinase-1, the key regulatory step in glycolysis.<sup>[26]</sup>

Because of this bypass, fructose metabolism is less tightly regulated. Rapid hepatic fructose metabolism generates intermediates that drive *de novo* lipogenesis, leading to triglyceride synthesis and hepatic fat accumulation.<sup>[27]</sup> Excessive fructose intake has been associated with increased very-low-density lipoprotein (VLDL) production, hypertriglyceridemia, and non-alcoholic fatty liver disease.<sup>[28]</sup> Additionally, fructose metabolism increases uric acid production, which may contribute to oxidative stress, endothelial dysfunction, and hypertension.<sup>[29]</sup>

### 1.3 Role of Insulin and Glycemic Load

Insulin plays a central role in maintaining glucose homeostasis. It regulates carbohydrate, lipid, and protein metabolism by promoting anabolic processes and inhibiting catabolic pathways.<sup>[30]</sup> Diets high in rapidly absorbable carbohydrates with a high glycemic index or glycemic load cause sharp postprandial spikes in blood glucose and insulin.<sup>[31]</sup> Repeated exposure to such spikes contributes to  $\beta$ -cell stress and progressive insulin resistance.<sup>[32]</sup>


Glycemic load reflects both the quality (glycemic index) and quantity of carbohydrates consumed. High-glycemic-load diets have been linked to increased risk of metabolic syndrome, cardiovascular disease, and certain cancers.<sup>[33]</sup> In contrast, diets rich in complex carbohydrates and dietary fiber produce slower glucose absorption and more stable insulin responses.<sup>[34]</sup>

### 1.4 Formation of Advanced Glycation End Products (AGEs)

Persistent hyperglycemia promotes non-enzymatic glycation of proteins, lipids, and nucleic acids, leading to the formation of advanced glycation end products (AGEs).<sup>[35]</sup> This process

begins with the reaction between reducing sugars and amino groups of proteins, forming unstable Schiff bases and Amadori products, which undergo further rearrangements to become irreversible AGEs.<sup>[36]</sup>

AGE accumulation alters protein structure and function, cross-links extracellular matrix proteins, and impairs enzymatic activity.<sup>[37]</sup> Binding of AGEs to their receptor (RAGE) activates intracellular signaling pathways, including NF- $\kappa$ B, which increases the production of pro-inflammatory cytokines and reactive oxygen species.<sup>[38]</sup> These processes contribute to endothelial dysfunction, vascular stiffness, nephropathy, retinopathy, and other chronic complications associated with prolonged hyperglycemia.<sup>[39]</sup>



**Figure 1: Comparative Metabolic Pathways of Dietary Glucose and Fructose.**

## 2. Metabolic Disorders

Excessive sugar intake plays a central role in the development of metabolic disorders, particularly obesity and its related complications. The metabolic consequences of chronic high sugar consumption extend beyond simple caloric excess and involve complex hormonal, biochemical, and neuroregulatory mechanisms. **Table 1** summarizes the types of dietary

sugars, their primary metabolic pathways, the organ systems affected, key mechanistic pathways, and resultant health outcomes.

## 2.1 Obesity

Obesity arises from a sustained imbalance between energy intake and expenditure. High sugar consumption contributes significantly to caloric excess because added sugars provide energy without inducing proportional satiety.<sup>[40]</sup> Sugar-sweetened beverages are especially problematic, as liquid calories produce weaker satiety signals compared to solid foods, leading to incomplete compensatory reductions in subsequent food intake.<sup>[41]</sup> This promotes a positive energy balance and progressive weight gain.

Fructose, in particular, has distinct metabolic effects that favor adiposity. Unlike glucose, fructose metabolism in the liver bypasses phosphofructokinase-1, the major rate-limiting enzyme in glycolysis.<sup>[42]</sup> This bypass allows unregulated entry of fructose-derived intermediates into pathways that stimulate *de novo* lipogenesis.<sup>[43]</sup> As a result, excessive fructose intake enhances hepatic triglyceride synthesis and increases very-low-density lipoprotein secretion.<sup>[44]</sup> These triglycerides can accumulate in adipose tissue and ectopic sites, promoting visceral fat deposition, which is metabolically more harmful than subcutaneous fat.<sup>[45]</sup>

Chronic high sugar intake also influences hormonal regulators of appetite and energy balance. Leptin, a hormone secreted by adipocytes, signals satiety to the hypothalamus and helps regulate long-term energy homeostasis.<sup>[46]</sup> Persistent overconsumption of sugar, especially fructose, has been associated with leptin resistance.<sup>[47]</sup> In this state, circulating leptin levels may be elevated due to increased adiposity, but hypothalamic sensitivity to leptin is reduced.<sup>[48]</sup> Consequently, appetite suppression becomes impaired, and energy expenditure may decrease, perpetuating weight gain.<sup>[49]</sup>

In addition to leptin resistance, high sugar intake affects other appetite-regulating hormones. Fructose has been shown to produce a weaker stimulation of insulin and lower suppression of ghrelin compared to glucose.<sup>[50]</sup> Because insulin and leptin act as satiety signals in the central nervous system, reduced stimulation may result in increased hunger and higher subsequent caloric intake.<sup>[51]</sup> Alterations in dopamine signaling within the brain's reward pathways may further enhance preference for sweet foods, reinforcing habitual overconsumption.<sup>[52]</sup>

Beyond adipose expansion, obesity induced by high sugar intake is often accompanied by chronic low-grade inflammation, adipocyte hypertrophy, and macrophage infiltration into adipose tissue.<sup>[53]</sup> These inflammatory processes contribute to systemic insulin resistance and increase the risk of progression to type 2 diabetes mellitus and cardiovascular disease.<sup>[54]</sup>

Overall, excessive sugar intake promotes obesity not only through increased caloric load but also through metabolic reprogramming, hormonal dysregulation, and central appetite signaling disturbances. Understanding these interconnected mechanisms is essential for clarifying how dietary sugars contribute to the global obesity epidemic and associated metabolic complications.

## 2.2 Type 2 Diabetes Mellitus

Type 2 diabetes mellitus (T2DM) is one of the most significant metabolic consequences of chronic excessive sugar consumption.<sup>[55]</sup> It is characterized by persistent hyperglycemia resulting from a combination of insulin resistance and progressive pancreatic  $\beta$ -cell dysfunction.<sup>[56]</sup> While genetic predisposition plays a role, dietary patterns rich in added sugars and refined carbohydrates substantially increase disease risk.<sup>[57]</sup>

Frequent consumption of high-sugar foods and beverages leads to repeated postprandial spikes in blood glucose and insulin.<sup>[58]</sup> Over time, chronic hyperinsulinemia reduces insulin sensitivity in peripheral tissues such as skeletal muscle, liver, and adipose tissue.<sup>[59]</sup> In insulin-resistant states, glucose uptake by muscle declines, hepatic gluconeogenesis remains inappropriately elevated, and lipolysis in adipose tissue increases.<sup>[60]</sup> These disturbances collectively contribute to sustained hyperglycemia.

Fructose contributes to T2DM development through distinct hepatic mechanisms.<sup>[61]</sup> As discussed earlier, fructose metabolism bypasses key glycolytic regulatory steps and drives *de novo* lipogenesis.<sup>[62]</sup> The resulting accumulation of hepatic triglycerides promotes hepatic insulin resistance.<sup>[63]</sup> When the liver becomes insulin resistant, it fails to suppress glucose production adequately, further exacerbating fasting hyperglycemia.<sup>[64]</sup> Additionally, increased circulating triglycerides and free fatty acids impair insulin signaling in skeletal muscle, worsening systemic insulin resistance.<sup>[65]</sup>

Chronic exposure to elevated glucose levels also induces glucotoxicity, which directly damages pancreatic  $\beta$ -cells.<sup>[66]</sup> Persistent hyperglycemia increases oxidative stress within  $\beta$ -

cells, which are particularly vulnerable due to relatively low antioxidant defense capacity.<sup>[67]</sup> Excess reactive oxygen species impair insulin gene expression, reduce insulin secretion, and promote  $\beta$ -cell apoptosis.<sup>[68]</sup> Simultaneously, lipotoxicity from elevated free fatty acids further compromises  $\beta$ -cell function.<sup>[69]</sup> The combined effect of glucotoxicity and lipotoxicity accelerates  $\beta$ -cell exhaustion, marking the transition from compensated insulin resistance to overt diabetes.<sup>[70]</sup>

Another important mechanism involves the formation of advanced glycation end products (AGEs). Persistent hyperglycemia enhances non-enzymatic glycation of proteins, leading to AGE accumulation in pancreatic tissue and vascular structures.<sup>[71]</sup> Interaction of AGEs with their receptor (RAGE) activates inflammatory signaling pathways, including NF- $\kappa$ B, increasing pro-inflammatory cytokine production.<sup>[72]</sup> This chronic low-grade inflammation further disrupts insulin signaling and contributes to vascular complications associated with diabetes.<sup>[73]</sup>

Epidemiological studies consistently show a strong association between high intake of sugar-sweetened beverages and increased risk of T2DM, independent of body weight in some analyses.<sup>[74]</sup> This suggests that beyond its contribution to obesity, excessive sugar intake may exert direct diabetogenic effects. High glycemic load diets also increase  $\beta$ -cell demand, promoting earlier functional decline.

In summary, excessive sugar consumption contributes to the development of type 2 diabetes mellitus through multiple interconnected mechanisms, including systemic insulin resistance, hepatic fat accumulation, oxidative stress, inflammation, and progressive  $\beta$ -cell dysfunction. These pathophysiological changes underscore the critical importance of reducing added sugar intake in preventing diabetes and its long-term complications.

### 2.3 Metabolic Syndrome

Metabolic syndrome represents a cluster of interrelated metabolic abnormalities that significantly increase the risk of type 2 diabetes mellitus and cardiovascular disease.<sup>[75]</sup> It is typically defined by the presence of central obesity, hyperglycemia, hypertension, elevated triglycerides, and reduced high-density lipoprotein (HDL) cholesterol.<sup>[76]</sup> Excessive sugar intake contributes directly and indirectly to the development of this syndrome through multiple overlapping mechanisms.<sup>[77]</sup>

One of the primary drivers is visceral adiposity. High consumption of added sugars, particularly fructose, promotes hepatic de novo lipogenesis and increases circulating triglycerides.<sup>[78]</sup> These triglycerides are transported and deposited in abdominal adipose tissue, leading to central obesity, which is a core component of metabolic syndrome.<sup>[79]</sup> Visceral fat is metabolically active and releases free fatty acids, inflammatory cytokines such as TNF- $\alpha$  and IL-6, and adipokines that impair insulin signaling pathways.<sup>[80]</sup>

Insulin resistance is a central feature of metabolic syndrome and is strongly influenced by high sugar intake.<sup>[81]</sup> Chronic hyperglycemia and hyperinsulinemia reduce insulin receptor sensitivity in muscle and liver tissues.<sup>[82]</sup> As insulin becomes less effective at facilitating glucose uptake and suppressing hepatic glucose output, blood glucose levels rise.<sup>[83]</sup> At the same time, insulin resistance in adipose tissue enhances lipolysis, increasing circulating free fatty acids, which further aggravate hepatic and muscular insulin resistance.<sup>[84]</sup> This creates a self-perpetuating metabolic cycle.

Dyslipidemia is another key component. Fructose-driven lipogenesis elevates very-low-density lipoprotein (VLDL) production in the liver, increasing plasma triglyceride levels.<sup>[85]</sup> Elevated triglycerides often occur alongside reduced HDL cholesterol, a combination strongly associated with atherogenic risk.<sup>[86]</sup> Additionally, small dense low-density lipoprotein (LDL) particles, which are more prone to oxidation and arterial deposition, are frequently observed in individuals with high sugar intake and insulin resistance.<sup>[87]</sup>

Hypertension within metabolic syndrome may also be linked to excessive sugar consumption.<sup>[88]</sup> Fructose metabolism increases uric acid production, which can impair endothelial nitric oxide availability, reducing vasodilation.<sup>[89]</sup> Elevated uric acid levels have been associated with vascular stiffness, endothelial dysfunction, and activation of the renin-angiotensin system, all of which contribute to increased blood pressure.<sup>[90]</sup>

Chronic low-grade inflammation further integrates these metabolic abnormalities.<sup>[91]</sup> Enlarged adipocytes and infiltrating macrophages in visceral fat secrete pro-inflammatory mediators that activate intracellular signaling pathways such as NF- $\kappa$ B and JNK.<sup>[92]</sup> These pathways interfere with insulin receptor signaling and exacerbate systemic metabolic dysfunction.<sup>[93]</sup> Oxidative stress generated by hyperglycemia and lipid accumulation amplifies this inflammatory environment.<sup>[94]</sup>

Importantly, metabolic syndrome is not merely a collection of isolated risk factors but a pathophysiological state driven by interconnected metabolic disturbances. Diets high in added sugars accelerate these processes by promoting energy excess, hepatic lipid accumulation, insulin resistance, and inflammatory activation.<sup>[95]</sup> As a result, individuals with high sugar intake are at substantially greater risk of progressing to overt type 2 diabetes mellitus and cardiovascular disease.<sup>[96]</sup>

In summary, excessive sugar consumption contributes to the development and progression of metabolic syndrome through mechanisms involving visceral adiposity, insulin resistance, dyslipidemia, hypertension, oxidative stress, and chronic inflammation. Addressing high sugar intake is therefore a critical component in preventing the clustering of cardiometabolic risk factors that define this condition.

**Table 1: Metabolic pathways and systemic effects of dietary sugars, detailing how different sugar types contribute to multi-organ damage through distinct metabolic mechanisms.**

Sugar Type	Primary Metabolism	Affected Organs / Systems	Key Mechanisms	Health Outcomes	Ref
<b>Glucose</b>	Glycolysis → Pyruvate → TCA cycle; stimulates insulin release	Liver, Muscle, Adipose, Pancreas, Brain, Heart	Hyperglycemia, insulin release, elevated glycemic load	Obesity, Type 2 Diabetes, Cognitive impairment, cardiovascular disease	[97-100]
<b>Fructose</b>	Liver via fructokinase → Fructose-1-phosphate → Triose-phosphate → De novo lipogenesis	Liver, Heart, Pancreas, Kidney, Brain	Lipogenesis, uric acid generation, insulin resistance, AGE formation	NAFLD, NASH, Dyslipidemia, Hypertension, CKD, Cognitive deficits	[101-104]
<b>Sucrose / Table Sugar</b>	Cleaved into glucose + fructose; combined effects	Multiple organs (systemic)	Hyperglycemia, lipogenesis, inflammation, oxidative stress	Obesity, Cardiovascular disease, Metabolic syndrome, Cognitive decline, Cancer risk	[67,105-107]
<b>Added Sugars / Sugar-sweetened beverages</b>	High glycemic load, rapid absorption	Liver, Brain, Heart, Kidneys, Gut	Insulin spikes, chronic inflammation, oxidative stress, gut	Obesity, Diabetes, NAFLD/NASH, Cardiovascular disease, Cognitive impairment, Cancer	[74,108-110]

			microbiota dysbiosis	risk	
--	--	--	-------------------------	------	--

### 3. Cardiovascular System

Excessive dietary sugar has emerged as a significant and independent risk factor for cardiovascular disease (CVD), encompassing conditions such as coronary artery disease, hypertension, and heart failure. The harmful effects of sugar on the cardiovascular system result from a combination of metabolic, inflammatory, hemodynamic, and oxidative mechanisms. These mechanisms often act synergistically, amplifying the risk of vascular damage and adverse cardiac outcomes over time.

#### 3.1 Dyslipidemia and Atherogenesis

High sugar intake, particularly from added sugars and sugar-sweetened beverages, promotes dyslipidemia, a central contributor to atherosclerosis.<sup>[111]</sup> Fructose is metabolized in the liver via pathways that bypass glycolytic regulation, stimulating *de novo* lipogenesis.<sup>[112]</sup> This process increases hepatic triglyceride production and enhances secretion of very-low-density lipoprotein (VLDL) particles into circulation.<sup>[113]</sup> Elevated triglycerides are often accompanied by an increase in small dense low-density lipoprotein (LDL) particles, which are highly atherogenic due to their susceptibility to oxidative modification and enhanced penetration into the arterial intima.<sup>[114]</sup> Concurrently, high sugar intake reduces high-density lipoprotein (HDL) cholesterol, impairing reverse cholesterol transport.<sup>[115]</sup> Together, these alterations accelerate plaque formation, increase arterial stiffness, and promote progression of atherosclerotic cardiovascular disease.

#### 3.2 Hypertension

Dietary sugar contributes to elevated blood pressure through multiple mechanisms, with fructose playing a particularly important role.<sup>[116]</sup> Metabolism of fructose in the liver generates uric acid, which inhibits endothelial nitric oxide synthase (eNOS) activity, reducing nitric oxide bioavailability and impairing vasodilation.<sup>[117]</sup> Elevated uric acid also stimulates the renin-angiotensin-aldosterone system, promoting vasoconstriction and sodium retention.<sup>[118]</sup> These effects are compounded by obesity-induced increases in sympathetic nervous system activity.<sup>[119]</sup> Collectively, these mechanisms result in sustained hypertension, a leading risk factor for myocardial infarction, stroke, and other cardiovascular events.

### 3.3 Insulin Resistance and Endothelial Dysfunction

Persistent high sugar intake induces insulin resistance, which significantly impacts vascular health. Insulin normally promotes vasodilation through endothelial nitric oxide release, but insulin-resistant states reduce this response, leading to impaired vascular tone.<sup>[120]</sup> Moreover, chronic hyperglycemia accelerates the formation of advanced glycation end products (AGEs), which cross-link extracellular matrix proteins in the vasculature and interact with the receptor for AGEs (RAGE).<sup>[121]</sup> Activation of RAGE triggers intracellular signaling pathways, including NF- $\kappa$ B, increasing oxidative stress, promoting inflammatory cytokine release, and further compromising endothelial integrity.<sup>[122]</sup> Endothelial dysfunction is an early step in atherogenesis and contributes to vascular stiffness, impaired microvascular circulation, and a higher risk of thrombotic events.<sup>[123]</sup>

### 3.4 Inflammation and Oxidative Stress

Excess sugar intake also promotes systemic inflammation and oxidative stress, which are closely linked to cardiovascular risk.<sup>[124]</sup> Visceral adiposity, which is often increased in individuals consuming high levels of sugar, secretes pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF- $\alpha$ ) and interleukin-6 (IL-6).<sup>[125]</sup> These cytokines exacerbate insulin resistance and directly affect endothelial cells, contributing to vascular dysfunction.<sup>[126]</sup> High glucose and fructose levels enhance reactive oxygen species (ROS) production in the liver, pancreas, and vascular endothelium, amplifying oxidative stress.<sup>[127]</sup> Oxidative stress damages lipids, proteins, and DNA in vascular tissues, accelerates plaque instability, and increases susceptibility to acute cardiovascular events such as myocardial infarction or stroke.<sup>[128]</sup>

### 3.5 Epidemiological Evidence

Population-level data support the mechanistic links between sugar consumption and cardiovascular disease.<sup>[111]</sup> The Global Burden of Disease Study 2019 highlighted that diets high in sugar-sweetened beverages contribute to millions of CVD-related deaths worldwide.<sup>[129]</sup> Longitudinal cohort studies demonstrate that individuals consuming more than 25% of their daily calories from added sugars have significantly higher risks of coronary heart disease and cardiovascular mortality compared to those consuming less than 10%.<sup>[130]</sup> Notably, these associations remain significant even after adjusting for total caloric intake and body mass index, indicating that sugar exerts direct cardiovascular effects beyond weight gain alone.<sup>[131]</sup>

#### 4. Liver Damage

The liver plays a central role in sugar metabolism, particularly in the processing of fructose, which is increasingly consumed in the form of sugar-sweetened beverages and processed foods.<sup>[62,132]</sup> Chronic overconsumption of sugar, especially fructose, has profound implications for liver health, contributing to the development of non-alcoholic fatty liver disease (NAFLD).<sup>[133]</sup> NAFLD encompasses a spectrum of hepatic disorders ranging from simple steatosis to non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and, in severe cases, hepatocellular carcinoma.<sup>[134]</sup> Recent global estimates indicate that approximately 25–30% of adults worldwide are affected by NAFLD, with prevalence rising sharply in populations with high dietary sugar consumption.<sup>[135]</sup>

##### 4.1 Fructose Metabolism and Hepatic Lipogenesis

Fructose is primarily metabolized in hepatocytes through the enzyme fructokinase, which converts it into fructose-1-phosphate, bypassing the key regulatory enzyme phosphofructokinase in glycolysis.<sup>[136]</sup> This bypass leads to unregulated production of triose-phosphate intermediates that serve as substrates for de novo lipogenesis (DNL), resulting in enhanced synthesis of triglycerides.<sup>[136,137]</sup> These triglycerides can accumulate in the liver, causing hepatic steatosis, or are secreted as very-low-density lipoprotein (VLDL) into the circulation, contributing to hypertriglyceridemia and systemic metabolic disturbances.<sup>[138]</sup> Studies indicate that individuals consuming high amounts of fructose may have a 30–50% increase in hepatic DNL, which strongly correlates with intrahepatic fat accumulation.<sup>[78]</sup>

##### 4.2 Hepatic Insulin Resistance

Fructose-induced fat accumulation in hepatocytes is a key driver of hepatic insulin resistance.<sup>[61]</sup> In this state, insulin fails to suppress gluconeogenesis, leading to persistent fasting hyperglycemia.<sup>[60]</sup> Moreover, the liver's impaired response to insulin exacerbates dyslipidemia and contributes to systemic insulin resistance, linking NAFLD closely with the pathogenesis of metabolic syndrome and type 2 diabetes mellitus.<sup>[139,140]</sup> Clinical studies have shown that individuals with NAFLD have a 2–3 times higher risk of developing T2DM, independent of overall obesity.<sup>[141]</sup>

##### 4.3 Oxidative Stress and Inflammation

Chronic high sugar intake generates reactive oxygen species (ROS) within hepatocytes, creating a state of oxidative stress.<sup>[142]</sup> ROS damages cellular macromolecules, including lipids, proteins, and DNA, and triggers inflammatory signaling pathways such as NF- $\kappa$ B,

which upregulates pro-inflammatory cytokines like TNF- $\alpha$ , IL-6, and IL-1 $\beta$ .<sup>[143]</sup> This inflammatory environment promotes progression from simple steatosis to NASH, characterized by hepatocyte injury, ballooning degeneration, and immune cell infiltration.<sup>[144]</sup> Persistent oxidative stress also activates hepatic stellate cells, stimulating collagen deposition and fibrosis, which may progress to cirrhosis over time.<sup>[145]</sup>

#### 4.4 Uric Acid and Liver Injury

Fructose metabolism also generates uric acid, which contributes to mitochondrial oxidative stress and impairs nitric oxide availability in hepatocytes.<sup>[101]</sup> Elevated uric acid levels have been implicated in worsening insulin resistance and promoting liver inflammation, creating a vicious cycle that accelerates NAFLD progression.<sup>[146]</sup> Epidemiological data suggest that individuals with hyperuricemia have a significantly higher prevalence of NAFLD compared to those with normal uric acid levels.<sup>[147]</sup>

#### 4.5 Epidemiological and Clinical Evidence

The rising prevalence of NAFLD parallels global sugar consumption trends. Studies indicate that consumption of sugar-sweetened beverages is associated with a 55% higher risk of developing NAFLD over 5–10 years, independent of body mass index.<sup>[148]</sup> NASH, the progressive inflammatory form of NAFLD, is increasingly observed in younger populations, reflecting early exposure to high-sugar diets.<sup>[149]</sup> NAFLD is now one of the leading causes of liver-related morbidity worldwide and is projected to become the primary indication for liver transplantation within the next decade.<sup>[150]</sup>

#### 4.6 Clinical Implications

Liver damage from excessive sugar intake has systemic metabolic consequences. Hepatic insulin resistance contributes to hyperglycemia, dyslipidemia, and increased cardiovascular risk.<sup>[151]</sup> Chronic inflammation and oxidative stress originating from the liver further exacerbate metabolic and vascular dysfunction.<sup>[152]</sup> Importantly, early intervention through dietary sugar reduction can reverse hepatic fat accumulation, improve insulin sensitivity, and prevent progression to NASH and fibrosis.<sup>[153]</sup> Lifestyle modification remains the cornerstone of management, highlighting the critical role of public health strategies to reduce sugar consumption globally.<sup>[154]</sup>

## 5. Neurological and Cognitive Effects

Excessive dietary sugar intake not only impacts metabolic and cardiovascular health but also has significant effects on the central nervous system (CNS).<sup>[77,155]</sup> Emerging evidence suggests that chronic high sugar consumption can alter brain structure and function, impair cognitive performance, and affect mood and behavior.<sup>[156,157]</sup> These effects are mediated through multiple mechanisms, including insulin resistance in the brain, neuroinflammation, oxidative stress, and dysregulation of neurotransmitter systems.<sup>[157]</sup>

### 5.1 Brain Insulin Resistance

Insulin is a critical regulator of neuronal energy metabolism, synaptic plasticity, and cognitive function.<sup>[158]</sup> High sugar intake, particularly from refined carbohydrates and sugar-sweetened beverages, leads to systemic hyperinsulinemia and peripheral insulin resistance, which may extend to the CNS.<sup>[159]</sup> Brain insulin resistance impairs glucose uptake by neurons and astrocytes, limiting energy availability in key regions such as the hippocampus and prefrontal cortex.<sup>[160]</sup> These areas are essential for learning, memory consolidation, and executive function.<sup>[161]</sup> Chronic insulin resistance in the brain has been linked to reduced synaptic plasticity, impaired long-term potentiation (LTP), and deficits in memory and attention in both animal models and human studies.<sup>[162]</sup>

### 5.2 Cognitive Impairment

Several animal studies have shown that diets high in sugar impair performance on tasks requiring spatial memory, object recognition, and learning.<sup>[163]</sup> In humans, high consumption of sugar-sweetened beverages is associated with decreased hippocampal volume, impaired verbal memory, and slower cognitive processing speed.<sup>[164]</sup> A meta-analysis of observational studies indicates that individuals with the highest sugar intake have a significantly higher risk of mild cognitive impairment and age-related memory decline.<sup>[165]</sup> Chronic hyperglycemia, insulin resistance, and associated inflammation appear to be central drivers of these cognitive deficits.<sup>[166]</sup>

### 5.3 Neuroinflammation and Oxidative Stress

High sugar diets increase oxidative stress and trigger neuroinflammatory pathways in the brain.<sup>[167]</sup> Excess glucose and fructose promote the formation of reactive oxygen species (ROS), which damage neuronal lipids, proteins, and DNA.<sup>[168]</sup> Moreover, the accumulation of advanced glycation end products (AGEs) in the CNS activates receptors for AGEs (RAGE) on neurons and glial cells, stimulating the release of pro-inflammatory cytokines such as

TNF- $\alpha$  and IL-6.<sup>[169]</sup> This chronic low-grade neuroinflammation contributes to synaptic dysfunction, neuronal loss, and impaired neurogenesis in regions critical for memory and learning.<sup>[124]</sup>

#### 5.4 Dopamine Reward Pathway and Addiction-like Behavior

High sugar intake also affects brain reward circuits, particularly those mediated by dopamine in the mesolimbic pathway.<sup>[170]</sup> Repeated consumption of sugar-rich foods activates dopamine release in the nucleus accumbens, creating pleasurable sensations that reinforce feeding behavior.<sup>[171]</sup> Over time, this can lead to neuroadaptations similar to those seen in drug addiction, including reduced dopamine receptor sensitivity.<sup>[172]</sup> These changes increase sugar-seeking behavior, reduce satiety signaling, and may contribute to compulsive overeating, further exacerbating metabolic dysfunction.<sup>[173]</sup>

#### 5.5 Alzheimer's Disease and Neurodegeneration

Emerging evidence suggests a link between high sugar consumption and increased risk of neurodegenerative diseases such as Alzheimer's disease (AD).<sup>[174,175]</sup> Chronic hyperglycemia and insulin resistance in the brain impair amyloid-beta clearance and promote tau hyperphosphorylation, hallmarks of AD pathology.<sup>[176]</sup> Some researchers refer to this phenomenon as "type 3 diabetes," highlighting the role of metabolic dysregulation in cognitive decline.<sup>[177]</sup> Epidemiological studies have found that individuals with high sugar intake, particularly from sugar-sweetened beverages, exhibit higher rates of cognitive decline and dementia later in life.<sup>[157]</sup>

#### 5.6 Epidemiological Evidence

Population-based studies support the association between high sugar consumption and adverse neurological outcomes. For example, longitudinal studies in adults demonstrate that excessive intake of sugar-sweetened beverages is associated with poorer memory performance, reduced hippocampal volume, and higher incidence of mild cognitive impairment.<sup>[164]</sup> In children and adolescents, high sugar diets have been linked to attention deficits, behavioral problems, and impaired academic performance.<sup>[178]</sup> These findings underscore that sugar's effects on the brain may begin early in life and persist into adulthood.

### 6. Inflammation and Oxidative Stress

Excessive sugar intake triggers systemic inflammation and oxidative stress, which serve as central mechanisms linking metabolic, cardiovascular, hepatic, and neurological dysfunction.

Chronic consumption of high levels of glucose and fructose initiates a cascade of molecular events that disrupt cellular homeostasis, damage tissues, and accelerate the development of non-communicable diseases. **Figure 2** depicts how hyperglycemia and lipid accumulation trigger oxidative stress (ROS) and inflammation, which in turn worsen insulin resistance and directly promote damage to the liver, heart, brain, and kidneys.

### 6.1 Mechanisms of Sugar-Induced Inflammation

High dietary sugar promotes chronic low-grade inflammation through multiple pathways. Excess glucose and fructose elevate circulating free fatty acids and triglycerides, which stimulate pro-inflammatory signaling in adipocytes and hepatocytes.<sup>[179]</sup> Enlarged adipocytes secrete cytokines such as tumor necrosis factor-alpha (TNF- $\alpha$ ), interleukin-6 (IL-6), and monocyte chemoattractant protein-1 (MCP-1), recruiting macrophages and perpetuating adipose tissue inflammation.<sup>[180]</sup> This inflammatory milieu impairs insulin signaling, contributing to insulin resistance in muscle, liver, and vascular tissues.<sup>[181]</sup>

Fructose metabolism specifically increases uric acid production, which can activate the NLRP3 inflammasome in immune cells.<sup>[182]</sup> Activation of this pathway further enhances the release of IL-1 $\beta$  and IL-18, reinforcing systemic inflammation.<sup>[183]</sup> Moreover, advanced glycation end products (AGEs) formed from persistent hyperglycemia interact with RAGE receptors on various cell types, triggering NF- $\kappa$ B-mediated transcription of pro-inflammatory genes.<sup>[184]</sup> This pathway is implicated in vascular inflammation, endothelial dysfunction, and organ-specific damage in the liver, pancreas, and brain.<sup>[185,186]</sup>

### 6.2 Oxidative Stress

Excess sugar intake enhances the production of reactive oxygen species (ROS), exceeding the antioxidant capacity of cells and causing oxidative stress. ROS can damage lipids, proteins, and DNA, impairing normal cellular function.<sup>[187]</sup> In the liver, oxidative stress contributes to the progression of NAFLD to non-alcoholic steatohepatitis (NASH) and fibrosis.<sup>[188]</sup> In the vascular system, ROS reduces nitric oxide bioavailability, promoting endothelial dysfunction, vasoconstriction, and hypertension.<sup>[189]</sup> In the central nervous system, oxidative stress disrupts neuronal integrity and synaptic function, contributing to cognitive decline.<sup>[190]</sup>

### 6.3 Cross-Talk Between Inflammation and Oxidative Stress

Inflammation and oxidative stress are tightly interconnected. Pro-inflammatory cytokines such as TNF- $\alpha$  activate NADPH oxidase and mitochondrial ROS production, while ROS


themselves further activate NF- $\kappa$ B and other inflammatory transcription factors.<sup>[191]</sup> This vicious cycle amplifies tissue damage across multiple organ systems, accelerating the progression of obesity, type 2 diabetes, cardiovascular disease, liver injury, and neurodegeneration.<sup>[192-194]</sup>

#### 6.4 Epidemiological and Clinical Evidence

Epidemiological studies link high sugar consumption with elevated markers of systemic inflammation, such as C-reactive protein (CRP), IL-6, and TNF- $\alpha$ . Individuals consuming diets high in sugar-sweetened beverages consistently show higher inflammatory biomarker levels, independent of body weight.<sup>[195]</sup> Elevated oxidative stress markers, including malondialdehyde (MDA) and 8-hydroxy-2'-deoxyguanosine (8-OHdG), are also observed in populations with high sugar intake, confirming the biochemical impact at the cellular level.<sup>[196]</sup> These changes correlate with increased risk for metabolic syndrome, cardiovascular events, liver disease, and cognitive impairment.<sup>[197]</sup>

#### 6.5 Clinical Implications

Targeting inflammation and oxidative stress is crucial for mitigating the systemic effects of high sugar intake. Reducing added sugar consumption decreases circulating cytokines, ROS production, and AGE formation, improving insulin sensitivity and vascular function.<sup>[124]</sup> Lifestyle interventions that combine dietary sugar restriction with antioxidant-rich foods and physical activity have been shown to lower inflammatory markers, reduce hepatic fat accumulation, and improve cognitive performance, highlighting the reversibility of sugar-induced damage when addressed early.<sup>[198]</sup>



**Figure 2: Central Role of Inflammation and Oxidative Stress in Sugar-Induced Organ Damage.**

## 7. Cancer Risk

Emerging evidence suggests that excessive sugar intake may increase the risk of several types of cancer through both direct and indirect mechanisms. While sugar itself is not carcinogenic, chronic high sugar consumption contributes to metabolic and hormonal environments that favor tumor development and progression.

### 7.1 Mechanistic Links

**Hyperinsulinemia and IGF-1:** High sugar intake induces repeated spikes in blood glucose and insulin. Chronic hyperinsulinemia increases circulating levels of insulin-like growth factor 1 (IGF-1), which stimulates cell proliferation and inhibits apoptosis.<sup>[109]</sup> Elevated IGF-1 signaling is implicated in the development of breast, colorectal, and pancreatic cancers.<sup>[199]</sup>

**Obesity and Adipokines:** Sugar-induced weight gain and visceral adiposity alter adipokine secretion, increasing leptin and reducing adiponectin.<sup>[200]</sup> Leptin promotes angiogenesis, inflammation, and tumor cell proliferation, while low adiponectin removes a protective anti-proliferative signal.<sup>[201]</sup> These hormonal changes create a microenvironment conducive to tumor growth.

**Chronic Inflammation:** Excess sugar consumption promotes systemic inflammation, characterized by elevated TNF- $\alpha$ , IL-6, and CRP.<sup>[190]</sup> Chronic inflammation increases DNA damage, supports tumor initiation, and enhances progression through pro-angiogenic and immunosuppressive pathways.<sup>[203]</sup>

**Advanced Glycation End Products (AGEs):** Persistent hyperglycemia leads to AGE formation. AGEs bind to RAGE on cells, activating oxidative stress and NF- $\kappa$ B-mediated transcription, which can promote carcinogenesis, particularly in tissues like the liver, pancreas, and colon.<sup>[204]</sup>

### 7.2 Epidemiological Evidence

Observational studies indicate a correlation between high sugar-sweetened beverage consumption and increased risk of certain cancers. For example.

**Colorectal cancer:** High dietary glycemic load and excessive sugar intake are associated with a modest but significant increase in risk.<sup>[205]</sup>


**Breast cancer:** Elevated sugar intake, particularly in postmenopausal women, has been linked to higher incidence rates, potentially via insulin and IGF-1 signaling.<sup>[206,207]</sup>

**Pancreatic cancer:** Studies suggest a link between chronic high sugar consumption, hyperinsulinemia, and pancreatic tumor development.<sup>[208]</sup>

While sugar is rarely considered a direct carcinogen, its role in creating a pro-tumorigenic metabolic and inflammatory environment highlights the importance of moderation, particularly in populations at high risk for obesity-related cancers.

## 8. Other Organ Systems and Health Effects

Excessive sugar consumption affects multiple organ systems beyond metabolism, cardiovascular health, liver, and the brain. Its systemic effects are mediated through mechanisms such as glycation, inflammation, oxidative stress, and microbiome dysregulation, which together compromise overall health. **Figure 3** summarizes the primary detrimental health outcomes resulting from long-term high dietary sugar intake across various organ systems.



**Figure 3: Multi-Organ Damage Associated with Chronic Excessive Sugar Consumption.**

### 8.1 Renal System

High sugar intake, particularly fructose, contributes to chronic kidney disease (CKD) and other renal dysfunctions.<sup>[209]</sup> Fructose metabolism increases uric acid production, which can impair endothelial function in renal vasculature and promote hypertension.<sup>[210]</sup> Persistent

hyperglycemia also accelerates the formation of advanced glycation end products (AGEs) in renal tissues, damaging glomerular cells and the extracellular matrix.<sup>[211]</sup> Over time, these changes contribute to glomerulosclerosis, proteinuria, and progressive kidney injury. Epidemiological studies have linked sugar-sweetened beverage consumption to a 30–40% higher risk of CKD in adults, independent of body mass index.<sup>[212]</sup>

## 8.2 Gut Microbiota

Dietary sugar significantly impacts the composition and function of the gut microbiota, which plays a critical role in metabolism, immunity, and systemic inflammation.<sup>[124,213]</sup> Excess sugar promotes the growth of pathogenic bacteria while reducing beneficial commensals such as Bifidobacteria and Lactobacilli.<sup>[214]</sup> This dysbiosis increases gut permeability (“leaky gut”), allowing bacterial endotoxins such as lipopolysaccharides (LPS) to enter circulation and trigger systemic inflammation.<sup>[215]</sup> Altered microbiota has also been associated with insulin resistance, obesity, and metabolic syndrome, demonstrating the indirect systemic effects of sugar through gut-mediated pathways.<sup>[216]</sup>

## 8.3 Skeletal System

High sugar intake negatively affects bone health.<sup>[206]</sup> Elevated blood glucose increases urinary calcium excretion, reducing mineral availability for bone formation.<sup>[219]</sup> Additionally, chronic inflammation induced by excessive sugar impairs osteoblast activity and stimulates osteoclast-mediated bone resorption.<sup>[217]</sup> Children and adolescents consuming large amounts of sugary beverages are at higher risk for reduced bone mineral density, increasing susceptibility to fractures and osteoporosis later in life.<sup>[220]</sup>

## 8.4 Skin Health

Excessive sugar accelerates skin aging and contributes to dermatological conditions.<sup>[221]</sup> The non-enzymatic glycation of collagen and elastin fibers forms AGEs, which stiffen connective tissue, reduce skin elasticity, and promote wrinkling.<sup>[222]</sup> Sugar-induced systemic inflammation can exacerbate conditions such as acne and eczema.<sup>[223]</sup> Long-term high sugar intake may therefore contribute to both aesthetic and structural skin damage.<sup>[224]</sup>

## 8.5 Immune System

High sugar diets impair immune function by affecting leukocyte activity and increasing oxidative stress.<sup>[225]</sup> Hyperglycemia can reduce neutrophil chemotaxis, phagocytosis, and pathogen-killing capacity, making individuals more susceptible to infections.<sup>[226]</sup> Chronic

inflammation driven by sugar intake may also dysregulate adaptive immunity, impairing antibody responses and prolonging recovery from illness.<sup>[227]</sup>

### 8.6 Reproductive Health

Excess sugar consumption has been associated with hormonal imbalances and reproductive dysfunction.<sup>[228]</sup> Insulin resistance and hyperinsulinemia can disrupt ovarian steroidogenesis, contributing to conditions such as polycystic ovary syndrome.<sup>[229]</sup> In men, high sugar diets have been linked to impaired sperm quality and erectile dysfunction, highlighting the broader endocrine impact of sugar-induced metabolic derangements.<sup>[230]</sup>

**Table 2** summarizes the organ-specific detrimental effects of chronic excessive sugar intake. Mechanisms include insulin resistance, oxidative stress, chronic inflammation, lipogenesis, uric acid production, and advanced glycation end-product formation.

**Table 2: Organ-specific pathologies resulting from chronic excessive sugar intake, summarizing the effects, mechanisms, and clinical outcomes across all major body systems.**

Organ / System	Effect of Excess Sugar	Mechanisms Involved	Clinical / Health Outcomes	Ref
Liver	Fat accumulation, inflammation	Fructose metabolism → de novo lipogenesis, ROS, uric acid, AGE formation	NAFLD, NASH, fibrosis, insulin resistance	[231,232]
Heart & Vessels	Atherosclerosis, hypertension	Dyslipidemia, endothelial dysfunction, chronic inflammation, oxidative stress	Coronary artery disease, stroke, hypertension	[233,234]
Pancreas	β-cell stress, insulin resistance	Chronic hyperglycemia, insulin overproduction	Type 2 diabetes, impaired glucose tolerance	[193,235]
Brain	Cognitive decline, memory impairment, reward pathway alteration	Brain insulin resistance, neuroinflammation, oxidative stress, dopamine dysregulation	Memory deficits, learning impairment, addiction-like eating behaviors	[164,236]
Kidneys	Glomerular damage, reduced filtration	Uric acid elevation, AGE formation, oxidative stress	Chronic kidney disease, proteinuria, hypertension	[237,238]
Gut / Microbiota	Dysbiosis, increased gut permeability	Altered microbiota composition, endotoxin leakage, inflammation	Metabolic syndrome, systemic inflammation	[213,239]
Bone & Skin	Reduced density, collagen glycation	Calcium excretion, inflammation, AGE-	Osteoporosis, fractures, premature	[240-242]

		mediated collagen crosslinking	skin aging	
<b>Reproductive System</b>	Hormonal imbalance, fertility issues	Insulin resistance, altered steroidogenesis	PCOS, reduced sperm quality, infertility	[243,244]
<b>Cancer Risk</b>	Tumor initiation and progression	Hyperinsulinemia, IGF-1 elevation, inflammation, ROS, AGEs	Increased risk of breast, colorectal, pancreatic cancers	[245,246]
<b>Systemic Mediators</b>	Chronic multi-organ damage	Inflammation, oxidative stress, insulin resistance, hormonal dysregulation	Multi-organ dysfunction, accelerated chronic disease development	[247,248]

## 9. Public Health Perspective and Recommendations

Excessive sugar consumption is a growing global public health concern, contributing to obesity, diabetes, cardiovascular disease, liver disorders, neurological dysfunction, and potentially cancer. Addressing sugar-related health risks requires a combination of population-level interventions, policy measures, and individual behavioral strategies.

### 9.1 Global Sugar Consumption Trends

Worldwide, sugar consumption has risen dramatically over the past few decades. According to the World Health Organization (WHO, 2023), the average global intake of free sugars exceeds 50 grams per day per person, far above the recommended limit of 25 grams ( $\approx$ 6 teaspoons) per day.<sup>[249]</sup> Sugar-sweetened beverages are a major contributor, especially in high-income countries, but increasingly in low- and middle-income countries where processed foods are more widely available.<sup>[14]</sup> Urbanization, increased availability of ultra-processed foods, and aggressive marketing have amplified sugar intake globally, particularly among children and adolescents.<sup>[250]</sup>

### 9.2 Health and Economic Implications

High sugar consumption is linked to the rising prevalence of obesity, type 2 diabetes, cardiovascular disease, and NAFLD, imposing significant healthcare costs.<sup>[251]</sup> The Global Burden of Disease Study 2019 estimated that diets high in sugar-sweetened beverages alone were responsible for over 180,000 deaths worldwide due to diabetes and cardiovascular complications.<sup>[252]</sup> Beyond morbidity and mortality, high sugar intake also contributes to reduced productivity, increased medical expenditure, and lower quality of life.<sup>[253]</sup>

### 9.3 Public Health Strategies

#### Policy Interventions

- I. **Sugar taxes:** Several countries have implemented excise taxes on sugar-sweetened beverages, which have been shown to reduce consumption by 10–20% in some populations.<sup>[15]</sup>
- II. **Labeling regulations:** Mandatory front-of-pack labeling of added sugars helps consumers make informed dietary choices.<sup>[254]</sup>
- III. **Marketing restrictions:** Limiting advertising of high-sugar foods to children can reduce early-life exposure and prevent lifelong habits.<sup>[255]</sup>

#### Dietary Guidelines and Education

- I. International health organizations recommend reducing added sugar intake to less than 10% of total daily calories, with an ideal target of 5% for additional health benefits.<sup>[256]</sup>
- II. Public education campaigns highlighting the risks of excessive sugar consumption and promoting healthier alternatives, such as water, unsweetened beverages, fruits, and whole foods, are essential.<sup>[257]</sup>
- III. School and workplace programs can promote sugar reduction by providing healthier food and beverage options and encouraging nutrition literacy.<sup>[258]</sup>

#### Behavioral and Individual Approaches

- I. Gradual reduction of sugar in the diet is more sustainable than abrupt elimination.<sup>[259]</sup>
- II. Encouraging consumption of fiber-rich foods, protein, and healthy fats can improve satiety and reduce sugar cravings.<sup>[99]</sup>
- III. Monitoring sugar intake through food diaries or digital apps can help individuals track consumption and make informed adjustments.<sup>[98]</sup>

### 9.4 Future Directions

Research should focus on understanding sugar's organ-specific and systemic effects, developing population-specific dietary recommendations, and evaluating the long-term outcomes of policy interventions. Personalized nutrition strategies based on metabolic, genetic, and behavioral factors may enhance the effectiveness of sugar reduction initiatives.<sup>[97]</sup>

## DISCUSSION

Over the ten-year period from 2015 to 2025, the scientific evidence linking excessive sugar consumption to adverse health outcomes has expanded substantially. Accumulating epidemiological, mechanistic, and clinical data consistently demonstrate that high intake of added sugars, particularly from sugar-sweetened beverages and ultra-processed foods, contributes to metabolic dysfunction, chronic inflammation, and increased risk of non-communicable diseases. The present review synthesizes these findings and highlights the biological plausibility underlying these associations.

One of the most consistently reported outcomes is the relationship between high sugar intake and obesity. Excess dietary sugar increases total caloric intake without proportionate satiety, thereby promoting positive energy balance.<sup>[108]</sup> Fructose-containing sugars, especially in liquid form, appear particularly problematic because fructose metabolism in the liver bypasses key regulatory steps of glycolysis, stimulating *de novo* lipogenesis.<sup>[260]</sup> This process enhances hepatic triglyceride synthesis, contributing to visceral adiposity and ectopic fat deposition.<sup>[261]</sup> Moreover, chronic high sugar intake has been linked to leptin resistance and impaired appetite regulation, reinforcing a cycle of overeating and weight gain.<sup>[262]</sup>

The metabolic consequences extend beyond adiposity. Strong evidence supports the association between high sugar intake and insulin resistance, a central defect in type 2 diabetes mellitus.<sup>[263]</sup> Repeated exposure to high glycemic loads induces frequent insulin surges, which over time may reduce insulin sensitivity in peripheral tissues.<sup>[264]</sup> Additionally, fructose-driven hepatic lipid accumulation exacerbates hepatic insulin resistance, promoting hyperglycemia.<sup>[265]</sup> Advanced glycation end products formed through chronic hyperglycemia further impair cellular function and contribute to microvascular and macrovascular complications.<sup>[266]</sup>

Cardiovascular risk is another major concern. Prospective cohort studies during the past decade have shown that higher consumption of added sugars correlates with elevated blood pressure, dyslipidemia, and increased cardiovascular mortality.<sup>[267]</sup> Mechanistically, sugar-induced hyperinsulinemia may activate the sympathetic nervous system and promote sodium retention, thereby increasing blood pressure.<sup>[268]</sup> Concurrently, hepatic overproduction of very-low-density lipoproteins contributes to hypertriglyceridemia, a recognized cardiovascular risk factor.<sup>[269]</sup> Chronic low-grade inflammation and oxidative stress induced

by excessive sugar intake may also accelerate endothelial dysfunction and atherosclerotic progression.<sup>[270]</sup>

Emerging evidence has further explored the potential link between high sugar consumption and cancer risk. Although sugar does not directly “cause” cancer, hyperinsulinemia and elevated insulin-like growth factor-1 levels may create a pro-proliferative environment that facilitates tumor growth.<sup>[271]</sup> Obesity, a consequence of chronic excess sugar intake, is itself a well-established risk factor for multiple cancers.<sup>[272]</sup> Additionally, persistent inflammation and oxidative stress may contribute to DNA damage and tumorigenesis.<sup>[273]</sup> While causality remains complex and multifactorial, the biological mechanisms suggest plausible pathways connecting chronic high sugar intake to increased cancer susceptibility.

Neurological and cognitive outcomes have also received growing attention. Experimental and observational studies suggest that diets high in refined sugars may impair memory and cognitive performance, potentially through insulin resistance within the brain and increased neuroinflammation.<sup>[164]</sup> Some evidence indicates that excessive sugar intake may influence reward pathways similarly to addictive substances, reinforcing habitual consumption patterns.<sup>[172]</sup> These findings warrant further investigation, particularly in younger populations where dietary habits are established early.

Despite the strong associations observed, it is important to acknowledge limitations within the existing literature. Many epidemiological studies rely on self-reported dietary assessments, which are subject to recall bias and measurement error. Confounding factors such as physical activity, overall dietary patterns, and socioeconomic status may also influence observed outcomes. Furthermore, the heterogeneity of sugar sources complicates interpretation. Naturally occurring sugars in whole fruits, accompanied by fiber and phytonutrients, do not appear to exert the same detrimental metabolic effects as added sugars in processed foods.<sup>[274]</sup> Therefore, public health messaging must differentiate between intrinsic and added sugars.

Intervention studies provide more direct evidence, demonstrating that reducing added sugar intake improves body weight, glycemic control, and lipid profiles.<sup>[275]</sup> Policy-level interventions, including taxation of sugar-sweetened beverages and reformulation initiatives, have shown promising results in lowering population-level sugar consumption.<sup>[15]</sup> However,

global intake remains above recommended limits in many regions, particularly among adolescents and young adults.<sup>[276]</sup>

Collectively, the evidence from 2015 to 2025 underscores that excessive added sugar consumption is not merely a source of “empty calories” but a significant modifiable risk factor for metabolic and cardiovascular diseases. The mechanistic pathways involving insulin resistance, hepatic lipogenesis, inflammation, oxidative stress, and advanced glycation provide biological coherence to epidemiological findings. Future research should focus on long-term randomized controlled trials, dose-response relationships, and interactions between sugar intake and genetic or environmental modifiers.

In summary, the detrimental effects of high sugar consumption are multifaceted and interrelated, influencing metabolic, cardiovascular, oncological, and neurological health. Reducing added sugar intake at both individual and population levels remains a critical strategy for preventing non-communicable diseases and improving global health outcomes.

## CONCLUSION

Excessive dietary sugar is a major threat to human health, affecting nearly every organ system. Chronic high intake contributes to obesity, type 2 diabetes, and metabolic syndrome through insulin resistance, hormonal imbalance, and dyslipidemia. It promotes cardiovascular disease, drives non-alcoholic fatty liver disease through fructose-induced lipogenesis and oxidative stress, and impairs brain function by disrupting insulin signaling and increasing neuroinflammation. Sugar also negatively impacts the kidneys, gut microbiota, immune function, and may increase cancer risk. Inflammation and oxidative stress are central mechanisms underlying these effects.

Rising global sugar consumption parallels the increase in chronic diseases, creating significant public health and economic burdens. Reducing added sugar intake through policy measures and healthier dietary choices is essential. Overall, limiting sugar consumption is a key modifiable strategy to protect long-term metabolic and systemic health.

## ACKNOWLEDGEMENTS

The study did not receive any grants or fundings.

## Competing Interests

None

**Authors' contributions**

**Md. Al Amin:** Project administration; supervision; conceptualization of the study; methodology; comprehensive literature search; writing—original draft, review, and editing; validation of references and information; Correspondence.

**Md. Rezwan Hossain and Moazzema Binta Bashar:** Literature collection and data extraction; critical analysis and interpretation of studies; manuscript review and editing.

**Md. Ismail Kabir:** Validation of references and information, visualization of figures and tables; writing—review and editing; resources; formal analysis of literature.

**REFERENCES**

1. Louie JCY. Sugar Reformulation in Solid Foods: Limitations and Challenges. *Nutr Bull*, 2025 Jun; 50(2): 345–56.
2. Erickson J, Slavin J. Total, added, and free sugars: are restrictive guidelines science-based or achievable? *Nutrients*, 2015 Apr; 7(4): 2866–78.
3. World Health Organization. Healthy diet [Internet]. Available from: <https://www.who.int/news-room/fact-sheets/detail/healthy-diet>
4. OECD F and AO of the UN. OECD-FAO Agricultural Outlook 2025-2034, 2025.
5. Ahmed SK, Mohammed RA. Obesity : Prevalence , causes , consequences , management, preventive strategies and future research directions. *Metab Open* [Internet], 2025; 27(April): 100375. Available from: <https://doi.org/10.1016/j.metop.2025.100375>
6. Faruque S, Tong J, Lacmanovic V, Agbonghae C, Minaya DM, Czaja K. The Dose Makes the Poison: Sugar and Obesity in the United States - a Review. *Polish J food Nutr Sci*, 2019; 69(3): 219–33.
7. Powell-Wiley TM, Poirier P, Burke LE, Després JP, Gordon-Larsen P, Lavie CJ, et al. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. *Circulation*, 2021 May; 143(21): e984–1010.
8. Siam NH, Snigdha NN, Tabasumma N, Parvin I. Diabetes Mellitus and Cardiovascular Disease: Exploring Epidemiology, Pathophysiology, and Treatment Strategies. *Rev Cardiovasc Med*, 2024 Dec; 25(12): 436.
9. Malik VS, Pan A, Willett WC, Hu FB. Sugar-sweetened beverages and weight gain in children and adults: a systematic review and meta-analysis. *Am J Clin Nutr*, 2013 Oct; 98(4): 1084–102.
10. Lara-castor L, Hearn MO, Cudhea F, Miller V, Shi P, Zhang J, et al. Burdens of type 2

- diabetes and cardiovascular disease attributable to sugar-sweetened beverages in 184 countries, 2025; 31(February).
11. Safiri S, Karamzad N, Kaufman JS, Bell AW, Nejadghaderi SA, Sullman MJM, et al. Prevalence, Deaths and Disability-Adjusted-Life-Years (DALYs) Due to Type 2 Diabetes and Its Attributable Risk Factors in 204 Countries and Territories, 1990-2019: Results From the Global Burden of Disease Study 2019. *Front Endocrinol (Lausanne)*, 2022; 13: 838027.
  12. Elamin A, Ansah JP. Projecting the burden of dental caries and periodontal diseases among the adult population in the United Kingdom using a multi-state population model. *Front public Heal*, 2023; 11: 1190197.
  13. Moynihan P. Sugars and Dental Caries: Evidence for Setting a Recommended Threshold for Intake. *Adv Nutr*, 2016 Jan; 7(1): 149–56.
  14. Ge C, Xiong J, Zhu R, Hong Z, He Y. Global burden of high sugar-sweetened beverage consumption among young adults. *Diabetol Metab Syndr*, 2025 Jul; 17(1): 259.
  15. Itria A, Borges SS, Rinaldi AEM, Nucci LB, Enes CC. Taxing sugar-sweetened beverages as a policy to reduce overweight and obesity in countries of different income classifications: a systematic review. *Public Health Nutr*, 2021 Nov; 24(16): 5550–60.
  16. Tamir O, Cohen-Yogev T, Furman-Assaf S, Endevelt R. Taxation of sugar sweetened beverages and unhealthy foods: a qualitative study of key opinion leaders' views. *Isr J Health Policy Res*, 2018 Jul; 7(1): 43.
  17. Röder P V, Wu B, Liu Y, Han W. Pancreatic regulation of glucose homeostasis. *Exp Mol Med*, 2016 Mar; 48(3): e219.
  18. Merz KE, Thurmond DC. Role of Skeletal Muscle in Insulin Resistance and Glucose Uptake. *Compr Physiol*, 2020 Jul; 10(3): 785–809.
  19. Kierans SJ, Taylor CT. Glycolysis : A multifaceted metabolic pathway and signaling hub. *J Biol Chem [Internet]*, 2024; 300(11): 107906. Available from: <https://doi.org/10.1016/j.jbc.2024.107906>
  20. McCommis KS, Finck BN. Mitochondrial pyruvate transport: a historical perspective and future research directions. *Biochem J*, 2015 Mar; 466(3): 443–54.
  21. Uehara K, Santoleri D, Whitlock AEG, Titchenell PM. Insulin Regulation of Hepatic Lipid Homeostasis. *Compr Physiol*, 2023 Jun; 13(3): 4785–809.
  22. Jensen J, Rustad PI, Kolnes AJ, Lai YC. The role of skeletal muscle glycogen breakdown for regulation of insulin sensitivity by exercise. *Front Physiol*, 2011; 2: 112.
  23. Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB, et al.

- Pathophysiology of Type 2 Diabetes Mellitus. *Int J Mol Sci*, 2020 Aug; 21(17).
24. Fazio S, Mercurio V, Tibullo L, Fazio V, Affuso F. Insulin resistance/hyperinsulinemia: an important cardiovascular risk factor that has long been underestimated. *Front Cardiovasc Med*, 2024; 11: 1380506.
  25. Fructose I. Intestinal Fructose and Glucose Metabolism in Health and Disease. : 1–35.
  26. Khitan Z, Kim DH. Fructose: a key factor in the development of metabolic syndrome and hypertension. *J Nutr Metab*, 2013; 2013: 682673.
  27. Geidl-Flueck B, Gerber PA. Fructose drives de novo lipogenesis affecting metabolic health. *J Endocrinol*, 2023 May; 257(2).
  28. Ter Horst KW, Serlie MJ. Fructose Consumption, Lipogenesis, and Non-Alcoholic Fatty Liver Disease. *Nutrients*, 2017 Sep; 9(9).
  29. Caliceti C, Calabria D, Roda A, Cicero AFG. Fructose Intake, Serum Uric Acid, and Cardiometabolic Disorders: A Critical Review. *Nutrients*, 2017 Apr; 9(4).
  30. James HA, Neill BTO, Nair KS. Review Insulin Regulation of Proteostasis and Clinical Implications. *Cell Metab [Internet]*, 2017; 26(2): 310–23. Available from: <http://dx.doi.org/10.1016/j.cmet.2017.06.010>
  31. Vlachos D, Malisova S, Lindberg FA, Karaniki G. Glycemic Index (GI) or Glycemic Load (GL) and Dietary Interventions for Optimizing Postprandial Hyperglycemia in Patients with T2 Diabetes: A Review. *Nutrients*, 2020 May; 12(6).
  32. Augustin LSA, Kendall CWC, Jenkins DJA, Willett WC, Astrup A. Nutrition , Metabolism & Cardiovascular Diseases Glycemic index , glycemic load and glycemic response : An International Scientific Consensus Summit from the International Carbohydrate Quality Consortium ( ICQC ) \*, 2015;
  33. Turati F, Galeone C, Augustin LSA, La Vecchia C. Glycemic Index, Glycemic Load and Cancer Risk: An Updated Meta-Analysis. *Nutrients*, 2019 Oct; 11(10).
  34. Lattimer JM, Haub MD. Effects of dietary fiber and its components on metabolic health. *Nutrients*, 2010 Dec; 2(12): 1266–89.
  35. Khalid M, Petroianu G, Adem A. Advanced Glycation End Products and Diabetes Mellitus: Mechanisms and Perspectives. *Biomolecules*, 2022 Apr; 12(4).
  36. Twarda-Clapa A, Olczak A, Białkowska AM, Koziółkiewicz M. Advanced Glycation End-Products (AGEs): Formation, Chemistry, Classification, Receptors, and Diseases Related to AGEs. *Cells*, 2022 Apr; 11(8).
  37. Kamml J, Ke C yu, Acevedo C, Kammer DS. Journal of the Mechanical Behavior of Biomedical Materials The influence of AGEs and enzymatic cross-links on the

- mechanical properties of collagen fibrils, 2023; 143(March).
38. Dong H, Zhang Y, Huang Y, Deng H. Pathophysiology of RAGE in inflammatory diseases. *Front Immunol*, 2022; 13: 931473.
  39. Cepas V, Collino M, Mayo JC, Sainz RM. Redox Signaling and Advanced Glycation Endproducts (AGEs) in Diet-Related Diseases. *Antioxidants (Basel, Switzerland)*, 2020 Feb; 9(2).
  40. Endy EJ, Yi S yun, Steffen BT, Shikany JM, Jacobs DR, Goins RK, et al. Nutrition , Metabolism & Cardiovascular Diseases Added sugar intake is associated with weight gain and risk of developing obesity over 30 years : The CARDIA study. *Nutr Metab Cardiovasc Dis [Internet]*, 2024; 34(2): 466–74. Available from: <https://doi.org/10.1016/j.numecd.2023.10.022>
  41. Sievenpiper JL, Purkayastha S, Grotz VL, Mora M, Zhou J, Hennings K, et al. Dietary Guidance , Sensory , Health and Safety Considerations When Choosing Low and No-Calorie Sweeteners, 2025;
  42. Li Z, Fan X, Gao F, Pan S, Ma X, Cheng H, et al. Fructose metabolism and its roles in metabolic diseases, inflammatory diseases, and cancer. *Mol Biomed*, 2025 Jun; 6(1): 43.
  43. Hannou SA, Haslam DE, Mckeown NM, Herman MA, Hannou SA, Haslam DE, et al. Fructose metabolism and metabolic disease Fructose metabolism and metabolic disease, 2018; 128(2): 545–55.
  44. Muriel P, López-Sánchez P, Ramos-Tovar E. Fructose and the Liver. *Int J Mol Sci*, 2021 Jun; 22(13).
  45. Janssen JAMJL. The Causal Role of Ectopic Fat Deposition in the Pathogenesis of Metabolic Syndrome. *Int J Mol Sci*, 2024 Dec; 25(24).
  46. Picó C, Palou M, Pomar CA, Rodríguez AM, Palou A. Leptin as a key regulator of the adipose organ. *Rev Endocr Metab Disord*, 2022 Feb; 23(1): 13–30.
  47. Shi Y nan, Liu Y jin, Xie Z, Zhang WJ. Fructose and metabolic diseases : too much to be good, 2021; 0(11).
  48. Obradovic M, Sudar-Milovanovic E, Soskic S, Essack M, Arya S, Stewart AJ, et al. Leptin and Obesity: Role and Clinical Implication. *Front Endocrinol (Lausanne)*, 2021; 12: 585887.
  49. Buscemi S, Buscemi C, Colombrita P, Randazzo C, Barile AM, Arnaldi G. Obesity : a disease of the ponderostat and the regulation of energy balance, 2025; 9.
  50. Luo S, Monterosso JR, Sarpelleh K, Page KA. Differential effects of fructose versus glucose on brain and appetitive responses to food cues and decisions for food rewards.

- Proc Natl Acad Sci U S A, 2015 May; 112(20): 6509–14.
51. Russo B, Menduni M, Borboni P, Picconi F, Frontoni S. Autonomic Nervous System in Obesity and Insulin-Resistance — The Complex Interplay between Leptin and Central Nervous System, 2021;
  52. Addiction F. brain sciences Food Addiction, 2024; 1–19.
  53. Ellulu MS, Patimah I, Khaza'ai H, Rahmat A, Abed Y. Obesity and inflammation: the linking mechanism and the complications. Arch Med Sci, 2017 Jun; 13(4): 851–63.
  54. Zatterale F, Longo M, Naderi J, Raciti GA, Desiderio A, Miele C, et al. Chronic Adipose Tissue Inflammation Linking Obesity to Insulin Resistance and Type 2 Diabetes. Front Physiol, 2019; 10: 1607.
  55. Veit M, Asten R Van, Olie A, Prinz P. The role of dietary sugars , overweight , and obesity in type 2 diabetes mellitus : a narrative review, 2022; (March).
  56. Weronika J, Majchrowicz G, Młynarska E, Czarnik W, Dzie N. Type 2 Diabetes Mellitus : New Pathogenetic Mechanisms , Treatment and the Most Important Complications, 2025;
  57. Clemente-Suárez VJ, Mielgo-Ayuso J, Martín-Rodríguez A, Ramos-Campo DJ, Redondo-Flórez L, Tornero-Aguilera JF. The Burden of Carbohydrates in Health and Disease. Nutrients, 2022 Sep; 14(18).
  58. DiNicolantonio JJ, O'Keefe JH. Added Sugars Drive Insulin Resistance, Hyperinsulinemia, Hypertension, Type 2 Diabetes and Coronary Heart Disease. Mo Med, 2022; 119(6): 519–23.
  59. Thomas DD, Corkey BE, Istfan NW, Apovian CM. Hyperinsulinemia: An Early Indicator of Metabolic Dysfunction. J Endocr Soc, 2019 Sep; 3(9): 1727–47.
  60. Hatting M, Tavares CDJ, Sharabi K, Rines AK, Puigserver P. Insulin regulation of gluconeogenesis. Ann N Y Acad Sci, 2018 Jan; 1411(1): 21–35.
  61. Softic S, Stanhope KL, Boucher J, Divanovic S, Lanaspa MA, Johnson RJ, et al. Fructose and hepatic insulin resistance. Crit Rev Clin Lab Sci, 2020 Aug; 57(5): 308–22.
  62. Jensen T, Abdelmalek MF, Sullivan S, Nadeau KJ, Green M, Roncal C, et al. Fructose and sugar: A major mediator of non-alcoholic fatty liver disease. J Hepatol, 2018 May; 68(5): 1063–75.
  63. Scherer T, Lindtner C, O'Hare J, Hackl M, Zielinski E, Freudenthaler A, et al. Insulin Regulates Hepatic Triglyceride Secretion and Lipid Content via Signaling in the Brain. Diabetes, 2016 Jun; 65(6): 1511–20.
  64. Lee S hae, Park S young, Choi CS. Insulin Resistance : From Mechanisms to Therapeutic

- Strategies, 2022; 15–37.
65. Elkanawati RY, Sumiwi SA, Levita J. Impact of Lipids on Insulin Resistance: Insights from Human and Animal Studies. *Drug Des Devel Ther*, 2024; 18: 3337–60.
66. Kim WH, Lee JW, Suh YH, Hong SH, Choi JS, Lim JH, et al. Exposure to chronic high glucose induces beta-cell apoptosis through decreased interaction of glucokinase with mitochondria: downregulation of glucokinase in pancreatic beta-cells. *Diabetes*, 2005 Sep; 54(9): 2602–11.
67. González P, Lozano P, Ros G, Solano F. Hyperglycemia and Oxidative Stress: An Integral, Updated and Critical Overview of Their Metabolic Interconnections. *Int J Mol Sci*, 2023 May; 24(11).
68. Mukai E, Fujimoto S, Inagaki N. Role of Reactive Oxygen Species in Glucose Metabolism Disorder in Diabetic Pancreatic  $\beta$ -Cells. *Biomolecules*, 2022 Sep; 12(9).
69. Vilas-Boas EA, Almeida DC, Roma LP, Ortis F, Carpinelli AR. Lipotoxicity and  $\beta$ -Cell Failure in Type 2 Diabetes: Oxidative Stress Linked to NADPH Oxidase and ER Stress. *Cells*, 2021 Nov; 10(12).
70. Oberhauser L, Maechler P. Lipid-Induced Adaptations of the Pancreatic Beta-Cell to Glucotoxic Conditions Sustain Insulin Secretion. *Int J Mol Sci*, 2021 Dec; 23(1).
71. Zhang Y, Zhang Z, Tu C, Chen X, He R. Advanced Glycation End Products in Disease Development and Potential Interventions, 2025;
72. Zhou M, Zhang Y, Shi L, Li L, Zhang D, Gong Z. Activation and modulation of the AGEs-RAGE axis: Implications for inflammatory pathologies and therapeutic interventions – A review. *Pharmacol Res [Internet]*, 2024; 206(May): 107282. Available from: <https://doi.org/10.1016/j.phrs.2024.107282>
73. Nedosugova L V, Markina Y V, Bochkareva LA, Kuzina IA, Petunina NA, Yudina IY, et al. Inflammatory Mechanisms of Diabetes and Its Vascular Complications. *Biomedicines*, 2022 May; 10(5).
74. Tseng TS, Lin WT, Gonzalez G V, Kao YH, Chen LS, Lin HY. Sugar intake from sweetened beverages and diabetes: A narrative review. *World J Diabetes*, 2021 Sep; 12(9): 1530–8.
75. Mohamed SM, Shalaby MA, El-shiekh RA, El-banna HA, Emam SR, Bakr AF. Metabolic syndrome: risk factors, diagnosis, pathogenesis, and management with natural approaches, 2023; 3(May).
76. Hamooya BM, Siame L, Muchaili L. Metabolic syndrome: epidemiology, mechanisms, and current therapeutic approaches, 2025; (September): 1–23.

77. Li F, Luo Q, Guo T, Zhou S, Cheng Z, Pan H, et al. The impact of high-sugar diets on central nervous system disorders: mechanisms, pathogenesis, and dietary implication. *Ann Med*, 2025 Dec; 57(1): 2561789.
78. Schwarz JM, Noworolski SM, Wen MJ, Dyachenko A, Prior JL, Weinberg ME, et al. Effect of a High-Fructose Weight-Maintaining Diet on Lipogenesis and Liver Fat. *J Clin Endocrinol Metab*, 2015 Jun; 100(6): 2434–42.
79. Hamooya BM, Siame L, Muchaili L, Masenga SK, Kirabo A. Metabolic syndrome: epidemiology, mechanisms, and current therapeutic approaches. *Front Nutr*, 2025; 12: 1661603.
80. Chait A, den Hartigh LJ. Adipose Tissue Distribution, Inflammation and Its Metabolic Consequences, Including Diabetes and Cardiovascular Disease. *Front Cardiovasc Med*, 2020; 7: 22.
81. Zhao X, An X, Yang C, Sun W, Ji H, Lian F. The crucial role and mechanism of insulin resistance in metabolic disease. *Front Endocrinol (Lausanne)*, 2023; 14: 1149239.
82. Lee Y, Fluckey JD, Chakraborty S, Muthuchamy M. Hyperglycemia- and hyperinsulinemia-induced insulin resistance causes alterations in cellular bioenergetics and activation of inflammatory signaling in lymphatic muscle. *FASEB J Off Publ Fed Am Soc Exp Biol*, 2017 Jul; 31(7): 2744–59.
83. Lewis GF, Carpentier AC, Pereira S, Hahn M, Giacca A. Perspective Direct and indirect control of hepatic glucose production by insulin. *Cell Metab [Internet]*, 2021; 33(4): 709–20. Available from: <https://doi.org/10.1016/j.cmet.2021.03.007>
84. Pal SC, Méndez-Sánchez N. Insulin resistance and adipose tissue interactions as the cornerstone of metabolic (dysfunction)-associated fatty liver disease pathogenesis. *World J Gastroenterol*, 2023 Jul; 29(25): 3999–4008.
85. Geidl-flueck B, Gerber PA. Fructose drives de novo lipogenesis affecting metabolic health, 2026;
86. Kosmas CE, Rodriguez Polanco S, Bousvarou MD, Papakonstantinou EJ, Peña Genao E, Guzman E, et al. The Triglyceride/High-Density Lipoprotein Cholesterol (TG/HDL-C) Ratio as a Risk Marker for Metabolic Syndrome and Cardiovascular Disease. *Diagnostics (Basel, Switzerland)*, 2023 Mar; 13(5).
87. Hirano T. Clinical significance of small dense low-density lipoprotein cholesterol measurement in type 2 diabetes. *J Diabetes Investig*, 2025 Mar; 16(3): 370–83.
88. Stanciu S, Rusu E, Miricescu D, Radu AC, Axinia B, Vrabie AM, et al. Links between Metabolic Syndrome and Hypertension: The Relationship with the Current Antidiabetic

- Drugs. *Metabolites*, 2023 Jan; 13(1).
89. Jia G, Aroor AR, Whaley-Connell AT, Sowers JR. Fructose and uric acid: is there a role in endothelial function? *Curr Hypertens Rep*, 2014 Jun; 16(6): 434.
90. Borghi C, Agnoletti D, Francesco A, Cicero G, Lurbe E, Virdis A. Uric Acid and Hypertension: a Review of Evidence and Future Perspectives for the Management of Cardiovascular Risk, 2022; (September): 1927–36.
91. Pietzner M, Kaul A, Henning AK, Kastenmüller G, Artati A, Lerch MM, et al. Comprehensive metabolic profiling of chronic low-grade inflammation among generally healthy individuals. *BMC Med*, 2017 Nov; 15(1): 210.
92. Turner L, Wanasinghe AI. Is Adipose Tissue Inflammation the Culprit of Obesity- - Associated Comorbidities? 2025;
93. Feng J, Lu S, Ou B, Liu Q, Dai J, Ji C, et al. The Role of JNk Signaling Pathway in Obesity-Driven Insulin Resistance. *Diabetes Metab Syndr Obes*, 2020; 13: 1399–406.
94. Sibony RW. Overview of oxidative stress and inflammation in diabetes, 2024; (September).
95. Parisse S, Coltorti E, Mischitelli M, Ferri F. New Insights into the Interplay Between Simple Sugars and Liver Diseases, 2025;
96. Shi Z, Zhu W, Lei Z, Yan X, Zhang X, Wei S, et al. Intake of Added Sugar from Different Sources and Risk of All-Cause Mortality and Cardiovascular Diseases: The Role of Body Mass Index. *J Nutr [Internet]*, 2024; 154(11): 3457–64. Available from: <https://doi.org/10.1016/j.tjnut.2024.09.017>
97. Munawaroh EF, Herawati DMD, Megawati G, Wijayakesuma A, Apriani L, Sofiatin Y, et al. Effectiveness of Personalized Nutrition on Management Diabetes Mellitus Type 2 and Prediabetes in Adults: A Systematic Review. *Diabetes Metab Syndr Obes*, 2025; 18: 2783–96.
98. Abeltino A, Riente A, Bianchetti G, Serantoni C, De Spirito M, Capezzone S, et al. Digital applications for diet monitoring, planning, and precision nutrition for citizens and professionals: a state of the art. *Nutr Rev*, 2025 Feb; 83(2): e574–601.
99. Alahmari LA. Dietary fiber influence on overall health, with an emphasis on CVD, diabetes, obesity, colon cancer, and inflammation. *Front Nutr*, 2024; 11: 1510564.
100. Han H sook, Kang G, Kim JS, Choi BH, Koo S hoi. Regulation of glucose metabolism from a liver-centric perspective, 2016; (December 2015): 1–10.
101. Russo E, Leoncini G, Esposito P, Garibotto G, Pontremoli R, Viazzi F. Fructose and Uric Acid: Major Mediators of Cardiovascular Disease Risk Starting at Pediatric Age. *Int J*

- Mol Sci, 2020 Jun; 21(12): 4479.
102. Musso G, Cassader M, Cohney S, Pinach S, Saba F, Gambino R. Emerging Liver–Kidney Interactions in Nonalcoholic Fatty Liver Disease. *Trends Mol Med* [Internet], 2015; 21(10): 645–62. Available from: <https://www.sciencedirect.com/science/article/pii/S1471491415001616>
  103. Disease N alcoholic FL. Organismal Fructose Metabolism in Health and Non-Alcoholic Fatty Liver Disease, 2020; 1–17.
  104. Liao Y, Davies NA, Bogle IDL. Computational Modeling of Fructose Metabolism and Development in NAFLD. *Front Bioeng Biotechnol*, 2020; 8: 762.
  105. Nakayama Y, Elliott KJ, Eguchi S. Cardiovascular Effects of Sucrose in Experimental Animals and Humans. *Hypertens (Dallas, Tex 1979)*, 2025 Nov; 82(11): 1799–808.
  106. Herman MA, Birnbaum MJ. Molecular aspects of fructose metabolism and metabolic disease. *Cell Metab* [Internet], 2021; 33(12): 2329–54. Available from: <https://www.sciencedirect.com/science/article/pii/S1550413121004290>
  107. Rosales-gómez CÁ, Martínez-carrillo BE, Guadarrama-lópez AL, Reséndiz-albor AA, Arciniega-martínez IM, Aguilar-rodríguez E. Impact of Sucrose Consumption on the Metabolic , Immune , and Redox Profile of Mice with Gestational Diabetes Mellitus, 2025; (Dm): 1–16.
  108. Witek K, Wydra K, Filip M. A High-Sugar Diet Consumption, Metabolism and Health Impacts with a Focus on the Development of Substance Use Disorder: A Narrative Review. *Nutrients*, 2022 Jul; 14(14).
  109. Babalola OO, Akinnusi E, Ottu PO, Bridget K, Oyubu G, Ajiboye SA, et al. The impact of ultra-processed foods on cardiovascular diseases and cancer: Epidemiological and mechanistic insights. *Asp Mol Med*, 2025 Jun; 5.
  110. Nafld L, Nash NS, Tseng T sung, Lin W ting, Ting P sheng, Huang C kuei, et al. Sugar-Sweetened Beverages and Artificially Sweetened, 2023; 1–14.
  111. Rippe JM, Angelopoulos TJ. Relationship between Added Sugars Consumption and Chronic Disease Risk Factors: Current Understanding. *Nutrients*, 2016 Nov; 8(11).
  112. Hengist A, Koumanov F, Gonzalez JT, Petersen O, Minokoshi Y. Fructose and metabolic health : governed by hepatic glycogen status ? 2019; 14(September 2018): 3573–85.
  113. Gugliucci A. Sugar and Dyslipidemia: A Double-Hit, Perfect Storm. *J Clin Med*, 2023 Aug; 12(17).
  114. Stoicescu C, Vacarescu C, Cozma D. HDL Function Versus Small Dense LDL: Cardiovascular Benefits and Implications. *J Clin Med*, 2025 Jul; 14(14).

115. Ouimet M, Barrett TJ, Fisher EA. Review Basic Mechanisms and Their Roles in Vascular Health and Disease, 2019; 1505–18.
116. Klein AV, Kiat H. The mechanisms underlying fructose-induced hypertension: a review. *J Hypertens*, 2015 May; 33(5): 912–20.
117. McMullen MK. OBM Integrative and Complementary Medicine Fructose Increases Uric Acid Contributing to Metabolic Syndrome - Herbal , Nutritional and Dietary Strategies to Reduce Uric Acid, 2018;
118. Wang XD, Liu J, Zhang YC, Wang Y, Wang Y, Ma D. Correlation between the elevated uric acid levels and circulating renin-angiotensin-aldosterone system activation in patients with atrial fibrillation. *Cardiovasc Diagn Ther*, 2021 Feb; 11(1): 50–5.
119. Brooks VL, Shi Z, Holwerda SW, Fadel PJ. Obesity-induced increases in sympathetic nerve activity: sex matters. *Auton Neurosci*, 2015 Jan; 187: 18–26.
120. Bahadoran Z, Mirmiran P, Kash K, Ghasemi A. Vascular nitric oxide resistance in type 2 diabetes, 2023; (June): 1–14.
121. Yamagishi SI, Matsui T. Role of Hyperglycemia-Induced Advanced Glycation End Product (AGE) Accumulation in Atherosclerosis. *Ann Vasc Dis*, 2018 Sep; 11(3): 253–8.
122. Deepu V, Rai V, Agrawal DK. Quantitative Assessment of Intracellular Effectors and Cellular Response in RAGE Activation. *Arch Intern Med Res*, 2024; 7(2): 80–103.
123. Młynarska E, Bojdo K, Frankenstein H, Krawiranda K. Endothelial Dysfunction as the Common Pathway Linking Obesity , Hypertension and Atherosclerosis, 2025; 1–34.
124. Ma X, Nan F, Liang H, Shu P, Fan X, Song X, et al. Excessive intake of sugar: An accomplice of inflammation. *Front Immunol*, 2022; 13: 988481.
125. Lopes HF, Corrêa-Giannella ML, Consolim-Colombo FM, Egan BM. Visceral adiposity syndrome. *Diabetol Metab Syndr*, 2016; 8: 40.
126. Lee J, Lee S, Zhang H, Hill MA, Zhang C, Park Y. Interaction of IL-6 and TNF- $\alpha$  contributes to endothelial dysfunction in type 2 diabetic mouse hearts. *PLoS One*, 2017; 12(11): e0187189.
127. Binjawhar DN, Alhazmi AT. Hyperglycemia-induced oxidative stress and epigenetic regulation of ET-1 gene in endothelial cells, 2023; (April): 1–9.
128. Valaitienė J, Cibulskienė AL. Oxidative Stress and Its Biomarkers in Cardiovascular Diseases. *Artery Res [Internet]*, 2024; 30(1): 1–12. Available from: <https://doi.org/10.1007/s44200-024-00062-8>
129. Lv J, Yang C, Yang X. The global burden of cardiovascular disease attributable to diet high in sugar-sweetened beverages among people aged 60 years and older: an analysis for

- the global burden of disease study 2019. *Front public Heal*, 2024; 12: 1366286.
130. Song S, Shim JE, Song Y. Association of added sugar intake with all-cause and cardiovascular disease mortality: a systematic review of cohort studies. *Nutr Res Pract*, 2022 May; 16(Suppl 1): S21–36.
  131. Rippe JM, Angelopoulos TJ. Sugars, obesity, and cardiovascular disease: results from recent randomized control trials. *Eur J Nutr*, 2016 Nov; 55(Suppl 2): 45–53.
  132. Baharuddin B. The Impact of Fructose Consumption on Human Health: Effects on Obesity, Hyperglycemia, Diabetes, Uric Acid, and Oxidative Stress With a Focus on the Liver. *Cureus*, 2024 Sep; 16(9): e70095.
  133. Lewis Lujan LM, Madrid Molina N, Guerrero-Magaña DE, Iloki Lewis AP, Reséndiz Zarazúa M, Rivera Vizcarra AE, et al. Role of excessive fructose consumption on liver health. *Clin Nutr Open Sci*, 2026 Feb; 65(8): 100613.
  134. Wal P, Yadav S, Jha SK, Singh A, Bhargavi B, Shivaram R, et al. Role of natural compounds in non-alcoholic fatty liver diseases (NAFLD): a mechanistic approach. *Egypt Liver J* 2025 151, 2025 Aug; 15(1): 50-.
  135. Wenqi Liu, Daokuan Zhai TZ. Meta-analysis of the association between major foods with added fructose and non-alcoholic fatty liver disease. *R Soc Chem*, 2023;
  136. Muriel P, López-sánchez P, Ramos-tovar E. Fructose and the Liver. *Int J Mol Sci*, 2021 Jul; 22(13): 6969.
  137. Dholariya SJ, Orrick JA. Biochemistry, Fructose Metabolism. *StatPearls*, 2022 Oct;
  138. Alves-Bezerra M, Cohen DE. Triglyceride metabolism in the liver. *Compr Physiol*, 2017 Jan; 8(1): 1.
  139. Lee SH, Park SY, Choi CS. Insulin Resistance: From Mechanisms to Therapeutic Strategies. *Diabetes Metab J*, 2021 Jan; 46(1): 15.
  140. Rinella ME, Lazarus J V., Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. *Hepatology*, 2023 Dec; 78(6): 1966.
  141. Cao L, An Y, Liu H, Jiang J, Liu W, Zhou Y, et al. Global epidemiology of type 2 diabetes in patients with NAFLD or MAFLD: a systematic review and meta-analysis. *BMC Med*, 2024 Dec; 22(1): 101.
  142. Mohan A, Hasan ZW, Galani HG, Afroze T, Niazi RK, Alfaki R, et al. Diabetes and liver cirrhosis: shared pathways and clinical implications – a narrative review. *Ann Med Surg*, 2025 Dec; 87(12): 8418.
  143. Bellanti F, Coda ARD, Trecca MI, Lo Buglio A, Serviddio G, Vendemiale G. Redox

- Imbalance in Inflammation: The Interplay of Oxidative and Reductive Stress. *Antioxidants*, 2025 Jun; 14(6): 656.
144. Savari F, Mard SA. Nonalcoholic steatohepatitis: A comprehensive updated review of risk factors, symptoms, and treatment. *Heliyon*, 2024 Apr; 10(7): e28468.
145. Powell EE, Wong VWS, Rinella M. Non-alcoholic fatty liver disease. *Lancet*, 2021 Jun; 397(10290): 2212–24.
146. Deji-Oloruntoba OO, Balogun JO, Elufioye TO, Ajakwe SO. Hyperuricemia and Insulin Resistance: Interplay and Potential for Targeted Therapies. *Int J Transl Med* 2025, Vol 5,, 2025 Jul; 5(3).
147. Fan J, Wang D. Serum uric acid and nonalcoholic fatty liver disease. *Front Endocrinol (Lausanne)*, 2024; 15: 1455132.
148. Chen H, Wang J, Li Z, Kei Lam CW, Xiao Y, Wu Q, et al. Consumption of Sugar-Sweetened Beverages Has a Dose-Dependent Effect on the Risk of Non-Alcoholic Fatty Liver Disease: An Updated Systematic Review and Dose-Response Meta-Analysis. *Int J Environ Res Public Health*, 2019 Jun; 16(12): 2192.
149. Wang J, Du J, Wang M, Jin M, Tang Z, Mao Y. Global, regional, and national burden of NAFLD in youths and young adults aged 15–39 years, 1990–2021, its attributable risk factors, and projections to 2035: a systematic analysis of the Global Burden of Disease Study 2021. *Front Nutr*, 2025 Jan; 12: 1509232.
150. Devarbhavi H, Asrani SK, Arab JP, Nartey YA, Pose E, Kamath PS. Global burden of liver disease: 2023 update. *J Hepatol*, 2023 Aug; 79(2): 516–37.
151. Zheng H, Sechi LA, Navarese EP, Casu G, Vidili G. Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review. *Cardiovasc Diabetol* 2024 231, 2024 Sep; 23(1): 346-.
152. Solleiro-Villavicencio H, Viurcos-Sanabria R, Aguayo-Guerrero JA, Pineda-Pérez PF, Méndez-García LA. Inflammation: a key mechanism connecting metabolic-associated steatotic liver disease and systemic arterial hypertension. *Front Immunol*, 2025; 16: 1620585.
153. Schwarz JM, Noworolski SM, Erkin-Cakmak A, Korn NJ, Wen MJ, Tai VW, et al. Effects of Dietary Fructose Restriction on Liver Fat, De Novo Lipogenesis, and Insulin Kinetics in Children with Obesity. *Gastroenterology*, 2017 Sep; 153(3): 743.
154. Ahmed IA, Mikail MA, Mustafa MR, Ibrahim M, Othman R. Lifestyle interventions for non-alcoholic fatty liver disease. *Saudi J Biol Sci*, 2019 Nov; 26(7): 1519.
155. Vigo D, Thornicroft G, Atun R. Association between intake of various sugar subtypes and

- common mental disorders: A large prospective study. *J Nutr Heal aging*, 2025 Oct; 29(10): 100647.
156. Knüppel A, Shipley MJ, Llewellyn CH, Brunner EJ. Sugar intake from sweet food and beverages, common mental disorder and depression: Prospective findings from the Whitehall II study. *Sci Rep*, 2017 Dec; 7(1).
157. Agarwal P, Ford CN, Leurgans SE, Beck T, Desai P, Dhana K, et al. Dietary Sugar Intake Associated with a Higher Risk of Dementia in Community-Dwelling Older Adults. *J Alzheimers Dis*, 2023 Oct; 95(4): 1417.
158. Ferrario CR, Reagan LP. Insulin-mediated synaptic plasticity in the CNS: Anatomical, functional and temporal contexts. *Neuropharmacology* [Internet], 2018; 136: 182–91. Available from: <https://www.sciencedirect.com/science/article/pii/S0028390817305907>
159. Lana A, Rodríguez-Artalejo F, Lopez-Garcia E. Consumption of Sugar-Sweetened Beverages Is Positively Related to Insulin Resistance and Higher Plasma Leptin Concentrations in Men and Nonoverweight Women. *J Nutr*, 2014; 144.
160. Chen W, Kullmann S, Rhea EM. Expanding the understanding of insulin resistance in brain and periphery. *Trends Endocrinol Metab*, 2026 Jan; 37(1): 17–30.
161. Sridhar S, Khamaj A, Asthana MK. Cognitive neuroscience perspective on memory: overview and summary. *Front Hum Neurosci*, 2023 Jul; 17: 1217093.
162. Spinelli M, Fusco S, Mainardi M, Scala F, Natale F, Lapenta R, et al. Brain insulin resistance impairs hippocampal synaptic plasticity and memory by increasing GluA1 palmitoylation through FoxO3a. *Nat Commun*, 2017 Dec; 8(1): 2009.
163. Coirini H, Rey M, Gonzalez Deniselle MC, Kruse MS. Long-Term Memory Function Impairments following Sucrose Exposure in Juvenile versus Adult Rats. *Biomedicines*, 2022 Nov; 10(11): 2723.
164. Gillespie KM, White MJ, Kemps E, Moore H, Dymond A, Bartlett SE. The Impact of Free and Added Sugars on Cognitive Function: A Systematic Review and Meta-Analysis. *Nutrients*, 2023 Dec; 16(1).
165. Liu H, Liu Y, Shi M, Zhou Y, Zhao Y, Xia Y. Meta-analysis of sugar-sweetened beverage intake and the risk of cognitive disorders. *J Affect Disord*, 2022 Sep; 313: 177–85.
166. Yu X, He H, Wen J, Xu X, Ruan Z, Hu R, et al. Diabetes-related cognitive impairment: Mechanisms, symptoms, and treatments. *Open Med*, 2025 Jan; 20(1): 20241091.
167. Jacques A, Chaaya N, Beecher K, Ali SA, Belmer A, Bartlett S. The impact of sugar consumption on stress driven, emotional and addictive behaviors. *Neurosci Biobehav Rev*

- [Internet], 2019; 103: 178–99. Available from: <https://www.sciencedirect.com/science/article/pii/S0149763418308613>
168. Mvelase Z, Luvuno M, Mabandla M V. Influence of high fructose intake on systemic and cognitive health across developmental stages: A review. *Endocr Metab Sci*, 2025 Dec; 19(10): 100256.
169. Wasilewska B, Mazur U, Kordas B, Mizia P, Juranek J. RAGE Axis in the Pathogenesis and Treatment of CNS Neurodegeneration in Long-Term Hyperglycemia. *Int J Mol Sci* 2026, Vol 27,, 2026 Feb; 27(4): 1881.
170. Murray S, Tulloch A, Criscitelli K, Avena NM. Recent studies of the effects of sugars on brain systems involved in energy balance and reward: Relevance to low calorie sweeteners. *Physiol Behav*, 2016 Oct; 164(Pt B): 504–8.
171. Rada P, Avena NM, Hoebel BG. Daily bingeing on sugar repeatedly releases dopamine in the accumbens shell. *Neuroscience*, 2005 Jan; 134(3): 737–44.
172. Qin D, Qi J, Shi F, Guo Z, Li H. About Sugar Addiction. *Brain Behav*, 2025 Jul; 15(7): e70338.
173. Sketriene D, Battista D, Lalert L, Kraiwattanapirom N, Thai HN, Leeboonngam T, et al. Compulsive-like eating of high-fat high-sugar food is associated with “addiction-like” glutamatergic dysfunction in obesity prone rats. *Addict Biol*, 2022 Sep; 27(5).
174. Moreira PI. High-sugar diets, type 2 diabetes and Alzheimer’s disease. *Curr Opin Clin Nutr Metab Care*, 2013 Jul; 16(4): 440–5.
175. Zhang S, Xiao Y, Cheng Y, Ma Y, Liu J, Li C, et al. Associations of sugar intake, high-sugar dietary pattern, and the risk of dementia: a prospective cohort study of 210,832 participants. *BMC Med*, 2024 Dec; 22(1): 298.
176. Mietelska-Porowska A, Domańska J, Want A, Więckowska-Gacek A, Chutorański D, Koperski M, et al. Induction of Brain Insulin Resistance and Alzheimer’s Molecular Changes by Western Diet. *Int J Mol Sci* 2022, Vol 23,, 2022 Apr; 23(9).
177. Kciuk M, Kruczkowska W, Gałęziewska J, Wanke K, Kałuzińska-Kołat Ź, Aleksandrowicz M, et al. Alzheimer’s Disease as Type 3 Diabetes: Understanding the Link and Implications. *Int J Mol Sci* 2024, Vol 25,, 2024 Nov; 25(22).
178. Kim Y, Chang H. Correlation between attention deficit hyperactivity disorder and sugar consumption, quality of diet, and dietary behavior in school children. *Nutr Res Pract*, 2011 Jun; 5(3): 236.
179. DiNicolantonio JJ, Mehta V, Onkaramurthy N, O’Keefe JH. Fructose-induced inflammation and increased cortisol: A new mechanism for how sugar induces visceral

- adiposity. *Prog Cardiovasc Dis*, 2018 May; 61(1): 3–9.
180. Uti DE, Atangwho IJ, Omang WA, Alum EU, Obeten UN, Udeozor PA, et al. Cytokines as key players in obesity low grade inflammation and related complications. *Obes Med*, 2025 Mar; 54: 100585.
181. Rehman K, Akash MSH. Mechanisms of inflammatory responses and development of insulin resistance: How are they interlinked? *J Biomed Sci*, 2016 Dec; 23(1).
182. Singh S, Sharma A, Guru B, Ahmad S, Gulzar F, Kumar P, et al. Fructose-mediated NLRP3 activation induces inflammation and lipogenesis in adipose tissue. *J Nutr Biochem*, 2022 Sep; 107: 109080.
183. Lopez-Castejon G. Control of the inflammasome by the ubiquitin system. *FEBS J*, 2020 Jan; 287(1): 11–26.
184. Gupta T, Singh TG, Singh R. Signaling complexity in diabetic neuropathy: a multitargeted perspective on pathogenesis and therapy. *J Recept Signal Transduct*, 2025 Dec;
185. Alkhatib AJ. A Review of the Histology, Physiology, and Pathology of the Pancreas. *PSM Vet Res*, 2024; 9(2): 24–36.
186. Dumnicka P, Maduzia D, Ceranowicz P, Olszanecki R, Drożdż R, Kuśnierz-Cabala B. The Interplay between Inflammation, Coagulation and Endothelial Injury in the Early Phase of Acute Pancreatitis: Clinical Implications. *Int J Mol Sci* 2017, Vol 18,, 2017 Feb; 18(2).
187. Bhatti JS, Sehrawat A, Mishra J, Sidhu IS, Navik U, Khullar N, et al. Oxidative stress in the pathophysiology of type 2 diabetes and related complications: Current therapeutics strategies and future perspectives. *Free Radic Biol Med*, 2022 May; 184: 114–34.
188. Akter S. Non-alcoholic Fatty Liver Disease and Steatohepatitis: Risk Factors and Pathophysiology. *Middle East J Dig Dis*, 2022 Apr; 14(2): 167.
189. Incalza MA, D’Oria R, Natalicchio A, Perrini S, Laviola L, Giorgino F. Oxidative stress and reactive oxygen species in endothelial dysfunction associated with cardiovascular and metabolic diseases. *Vascul Pharmacol*, 2018 Jan; 100: 1–19.
190. Xu S, Gao Z, Jiang L, Li J, Qin Y, Zhang D, et al. High glucose- or AGE-induced oxidative stress inhibits hippocampal neuronal mitophagy through the Keap1–Nrf2–PHB2 pathway in diabetic encephalopathy. *Sci Rep*, 2024; 14(1): 1–17.
191. Lyon U De, Micheau O, Ladik M, Valenta H, Erard M, Vandenabeele P, et al. From TNF-induced signaling to NADPH oxidase enzyme activity: Methods to investigate protein complexes involved in regulated cell death modalities, 2023; (April): 1–21.

192. Wang Z, Zan W, Fan Z, Wang S. Relationship between hepatic lipid accumulation and type 2 diabetes mellitus. *Biomed Pharmacother*, 2025 Dec; 193: 118723.
193. Giri B, Dey S, Das T, Sarkar M, Banerjee J, Dash SK. Chronic hyperglycemia mediated physiological alteration and metabolic distortion leads to organ dysfunction, infection, cancer progression and other pathophysiological consequences: An update on glucose toxicity. *Biomed Pharmacother*, 2018 Nov; 107: 306–28.
194. de Lima EP, Moretti RC, Torres Pomini K, Laurindo LF, Sloan KP, Sloan LA, et al. Glycolipid Metabolic Disorders, Metainflammation, Oxidative Stress, and Cardiovascular Diseases: Unraveling Pathways. *Biol* 2024, Vol 13,, 2024 Jul; 13(7).
195. Lin WT, Kao YH, Li MS, Luo T, Lin HY, Lee CH, et al. Sugar-Sweetened Beverages Intake, Abdominal Obesity, and Inflammation among US Adults without and with Prediabetes—An NHANES Study. *Int J Environ Res Public Health*, 2022 Jan; 20(1): 681.
196. Goriuc A, Cojocaru KA, Luchian I, Ursu RG, Butnaru O, Foia L. Using 8-Hydroxy-2'-Deoxyguanosine (8-OHdG) as a Reliable Biomarker for Assessing Periodontal Disease Associated with Diabetes. *Int J Mol Sci*, 2024 Feb; 25(3): 1425.
197. Zouridis S, Nasir AB, Aspichueta P, Syn WK. The Link between Metabolic Syndrome and the Brain. *Digestion*, 2024 Jun; 106(3): 203.
198. Sarathi V, Kolly A, Chaithanya HB, Dwarakanath CS. High rates of diabetes reversal in newly diagnosed Asian Indian young adults with type 2 diabetes mellitus with intensive lifestyle therapy. *J Nat Sci Biol Med*, 2017; 8(1): 60.
199. Key TJ, Appleby PN, Reeves GK, Roddam AW, Helzlsouer KJ, Alberg AJ, et al. Glucose-dependent insulin-like growth factor 1 secretion promotes breast cancer cell tumorigenesis. *Life Sci*, 2025 Dec; 382(6): 124020.
200. Senkus KE, Crowe-white KM. Changes in adiponectin : leptin ratio among older adults with obesity following a 12-month exercise and diet intervention Study participants, 2022; (May): 1–7.
201. Kounatidis D, Vallianou NG, Karampela I, Grivakou E, Dalamaga M. The intricate role of adipokines in cancer-related signaling and the tumor microenvironment: Insights for future research. *Semin Cancer Biol*, 2025 Aug; 113(4): 130–50.
202. Phosat C, Panprathip P, Chumpathat N, Prangthip P, Chantratita N, Soonthornworasiri N, et al. Elevated C-reactive protein, interleukin 6, tumor necrosis factor alpha and glyceimic load associated with type 2 diabetes mellitus in rural Thais: a cross-sectional study. *BMC Endocr Disord* 2017 171, 2017 Jul; 17(1): 44-.
203. Ramteke P, Deb A, Shepal V, Bhat MK. Hyperglycemia Associated Metabolic and

- Molecular Alterations in Cancer Risk, Progression, Treatment, and Mortality. *Cancers* 2019, Vol 11., 2019 Sep; 11(9).
204. Waghela BN, Vaidya FU, Ranjan K, Chhipa AS, Tiwari BS, Pathak C. AGE-RAGE synergy influences programmed cell death signaling to promote cancer. *Mol Cell Biochem*, 2021 Feb; 476(2): 585–98.
205. Feng T, Luo Q, Liu Y, Jin Z, Skwarchuk D, Lee R, et al. Fructose and glucose from sugary drinks enhance colorectal cancer metastasis via SORD. *Nat Metab*, 2025 Oct; 7(10): 2018–32.
206. Tazeoğlu A, Demir EG. Is carbohydrate consumption a risk factor for breast cancer? *Clin Sci Nutr*, 2025 Feb; 1–8.
207. Anil A, Raheja R, Gibu D, Raj AS, Spurthi S. Uncovering the Links Between Dietary Sugar and Cancer: A Narrative Review Exploring the Impact of Dietary Sugar and Fasting on Cancer Risk and Prevention. *Cureus*, 2024 Aug; 16(8): e67434.
208. Zhang AMY, Xia YH, Lin JSH, Chu KH, Wang WCK, Ruitter TJJ, et al. Hyperinsulinemia acts via acinar insulin receptors to initiate pancreatic cancer by increasing digestive enzyme production and inflammation. *Cell Metab*, 2023 Dec; 35(12): 2119-2135.e5.
209. Yani A, Putri. The Impact of Excessive Fructose Consumption on Kidney Health: A Narrative Review. *J Ris Kualitatif dan Promosi Kesehatan*, 2023 Jul; 2(2): 67–78.
210. Jalili-Moghaddam S, Mearns G, Plank LD, Tautolo ES, Rush E. Pacific Islands Families Study: Serum Uric Acid in Pacific Youth and the Associations with Free-Sugar Intake and Appendicular Skeletal Muscle Mass. *Nutr*, 2025 Jan; 17(1): 54.
211. Wu T, Ding L, Andoh V, Zhang J, Chen L. The Mechanism of Hyperglycemia-Induced Renal Cell Injury in Diabetic Nephropathy Disease: An Update. *Life* 2023, Vol 13., 2023 Feb; 13(2).
212. Rebholz CM, Young BA, Katz R, Tucker KL, Carithers TC, Norwood AF, et al. Patterns of beverages consumed and risk of incident kidney disease. *Clin J Am Soc Nephrol*, 2019 Jan; 14(1): 49–56.
213. Satokari R. High Intake of Sugar and the Balance between Pro- and Anti-Inflammatory Gut Bacteria. *Nutrients*, 2020 May; 12(5): 1348.
214. Angarita-Díaz M del P, Fong C, Bedoya-Correa CM, Cabrera-Arango CL. Does high sugar intake really alter the oral microbiota?: A systematic review. *Clin Exp Dent Res*, 2022 Dec; 8(6): 1376.
215. Park JE, Park HY, Kim YS, Park M. The Role of Diet, Additives, and Antibiotics in

- Metabolic Endotoxemia and Chronic Diseases. *Metabolites*, 2024 Dec; 14(12): 704.
216. Kawano Y, Edwards M, Huang Y, Bilate AM, Araujo LP, Tanoue T, et al. Microbiota imbalance induced by dietary sugar disrupts immune-mediated protection from metabolic syndrome. *Cell*, 2022 Sep; 185(19): 3501-3519.e20.
217. DiNicolantonio JJ, Mehta V, Zaman S Bin, O'Keefe JH. Not Salt But Sugar As Aetiological In Osteoporosis: A Review. *Mo Med*, 2018 May; 115(3): 247.
218. Ahn H, Park YK. Sugar-sweetened beverage consumption and bone health: a systematic review and meta-analysis. *Nutr J*, 2021 Dec; 20(1): 41.
219. Lee SA, Lagos LV, Bedford MR, Stein HH. Increasing calcium from deficient to adequate concentration in diets for gestating sows decreases digestibility of phosphorus and reduces serum concentration of a bone resorption biomarker. *J Anim Sci*, 2020; 98(3): skaa076.
220. Chen L, Liu R, Zhao Y, Shi Z. High Consumption of Soft Drinks Is Associated with an Increased Risk of Fracture: A 7-Year Follow-Up Study. *Nutrients*, 2020 Feb; 12(2): 530.
221. Dolata N, Balcer B, Liszka P, Pakuła M, Weimann M, Kruczkowska A, et al. The Impact of Excessive Sugar Consumption on Skin Health Analysis of Biological Mechanisms and Dermatological Effects. *J Educ Heal Sport*, 2024 Dec; 76: 56626.
222. Sloseris D, Forde NR. AGEing of collagen: The effects of glycation on collagen's stability, mechanics and assembly. *Matrix Biol*, 2025 Feb; 135(6): 153–60.
223. Yaseen MD, Chen H hsiang, Alkhayat AW. Sugar Consumption and Acne : Unravelling the Complex Sugar-Skin Relationship in the Adolescent Population, 2024; 1–18.
224. Li WZ, Liu XX, Shi YJ, Wang XR, Li L, Tai ML, et al. Unveiling the mechanism of high sugar diet induced advanced glycosylation end products damage skin structure via extracellular matrix–receptor interaction pathway. *J Cosmet Dermatol*, 2024 Jul; 23(7): 2496–508.
225. Cecerska-heryć E, Engwert W, Michałow J, Marciniak J, Birger R, Serwin N, et al. Oxidative stress markers and inflammation in type 1 and 2 diabetes are affected by BMI , treatment type , and complications, 2025; 1–20.
226. Jafar N, Edriss H, Nugent K. The effect of short-term hyperglycemia on the innate immune system. *Am J Med Sci*, 2016 Feb; 351(2): 201–11.
227. Vaibhav, Nishad SS, Dongare D, Tripathi ACP, Tripathi T, Tripathi P. Deciphering the intricacies of immune system dysfunction and its impact on diabetes mellitus: Revisiting the communication strategies to manage diabetes mellitus. *Heal Sci Rev [Internet]*, 2024; 13: 100201. Available from: <https://www.wjpr.net>

[//www.sciencedirect.com/science/article/pii/S2772632024000540](https://www.sciencedirect.com/science/article/pii/S2772632024000540)

228. Goran MI, Plows JF, Ventura EE. Effects of consuming sugars and alternative sweeteners during pregnancy on maternal and child health: evidence for a secondhand sugar effect. *Proc Nutr Soc*, 2018 Aug; 78(3): 262.
229. Chen Y, Sun X, Xia X, Chen K, Zeng F. The pathogenesis, therapeutic targets and drugs of polycystic ovary syndrome. *Front Endocrinol (Lausanne)*, 2026 Jan; 16: 1722649.
230. Win WKY, Wong MW, Benny P, Huang Z. Sweet Drinks, Sour Consequences: The Impact of Sugar-Sweetened Beverages on Sperm Health, a Narrative Review. *Nutr* 2025, Vol 17,, 2025 May; 17(10).
231. Lodge M, Dykes R, Kennedy A. Regulation of Fructose Metabolism in Nonalcoholic Fatty Liver Disease. *Biomolecules*, 2024 Jul; 14(7).
232. Federico A, Rosato V, Masarone M, Torre P, Dallio M, Romeo M, et al. The Role of Fructose in Non-Alcoholic Steatohepatitis: Old Relationship and New Insights. *Nutrients*, 2021 Apr; 13(4).
233. Li Y, Liu Y, Liu S, Gao M, Wang W, Chen K, et al. Diabetic vascular diseases : molecular mechanisms and therapeutic strategies, 2023; (February).
234. Petrie JR, Guzik TJ, Touyz RM. Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms. *Can J Cardiol*, 2018 May; 34(5): 575–84.
235. Dlodla P V, Mabhida SE, Ziqubu K, Nkambule BB, Mazibuko-Mbeje SE, Hanser S, et al. Pancreatic  $\beta$ -cell dysfunction in type 2 diabetes: Implications of inflammation and oxidative stress. *World J Diabetes*, 2023 Mar; 14(3): 130–46.
236. Qin D. Sugar Addiction : Neural Mechanisms and Health Implications, 2025; 1–9.
237. Hsieh MH, Yang JF, Lin WY, Chien HH, Kuo MC, Chang NC, et al. Fasting sugar, blood pressure, and uric acid are factors related to positive proteinuria and an impaired eGFR. *J Chinese Med Assoc [Internet]*, 2017; 80(12): 782–9. Available from: <https://www.sciencedirect.com/science/article/pii/S1726490117302319>
238. Thomas MC, Brownlee M, Susztak K, Sharma K, Jandeleit-Dahm KAM, Zoungas S, et al. Diabetic kidney disease. *Nat Rev Dis Prim*, 2015 Jul; 1: 15018.
239. Do MH, Lee E, Oh MJ, Kim Y, Park HY. High-Glucose or -Fructose Diet Cause Changes of the Gut Microbiota and Metabolic Disorders in Mice without Body Weight Change. *Nutrients*, 2018 Jun; 10(6).
240. Cavati G, Pirrotta F, Merlotti D, Mingiano C, Ceccarelli E, Calabrese M, et al. Role of Advanced Glycation End-Products and Oxidative Stress in Type-2-Diabetes-Induced Bone Fragility and Implications on Fracture Risk Stratification, 2023;

241. Chaudhuri J, Bains Y, Guha S, Kahn A, Hall D, Bose N, et al. The Role of Advanced Glycation End Products in Aging and Metabolic Diseases: Bridging Association and Causality. *Cell Metab* [Internet], 2018; 28(3): 337–52. Available from: <https://www.sciencedirect.com/science/article/pii/S1550413118305151>
242. Li ZP, Luo C, Yu XM, Ye LY, Sun D, Duan CZ, et al. Diabetic bone fragility through advanced glycation end product-collagen axis: Mechanisms and therapy of sodium glucose cotransporter 2 inhibitors. *World J Diabetes*, 2025 Oct; 16(10): 111813.
243. Skoracka K, Ratajczak AE, Rychter AM, Dobrowolska A, Krela-Kaźmierczak I. Female Fertility and the Nutritional Approach: The Most Essential Aspects. *Adv Nutr* [Internet], 2021; 12(6): 2372–86. Available from: <https://www.sciencedirect.com/science/article/pii/S2161831322005129>
244. Zańko A, Siewko K, Krętowski AJ, Milewski R. Lifestyle, Insulin Resistance and Semen Quality as Co-Dependent Factors of Male Infertility. *Int J Environ Res Public Health*, 2022 Dec; 20(1).
245. Zhang AMY, Wellberg EA, Kopp JL, Johnson JD. Hyperinsulinemia in Obesity, Inflammation, and Cancer. *Diabetes Metab J*, 2021 May; 45(3): 285–311.
246. Jacobo-Tovar E, Medel-Sánchez A, Durán-Castillo C, Guardado-Mendoza R. Insulin resistance in cancer risk and prognosis. *Semin Cancer Biol* [Internet], 2025; 114: 73–87. Available from: <https://www.sciencedirect.com/science/article/pii/S1044579X25000872>
247. Liu J, Li K, Yi Z, Wang C. Oxidative – Inflammatory Crosstalk and Multi-Target Natural Agents : Decoding Diabetic Vascular Complications, 2025. 1–35 p.
248. Verdile G, Keane KN, Cruzat VF, Medic S, Sabale M, Rowles J, et al. Inflammation and Oxidative Stress: The Molecular Connectivity between Insulin Resistance, Obesity, and Alzheimer’s Disease. *Mediators Inflamm*, 2015; 2015: 105828.
249. World Health Organization. WHO calls on countries to reduce sugars intake among adults and children [Internet]. Available from: <https://www.who.int/news/item/04-03-2015-who-calls-on-countries-to-reduce-sugars-intake-among-adults-and-children>
250. Mescoloto SB, Pongiluppi G, Domene SMÁ. Ultra-processed food consumption and children and adolescents’ health. *J Pediatr (Rio J)*, 2024; 100 Suppl 1(Suppl 1): S18–30.
251. Malik VS, Popkin BM, Bray GA, Després JP, Hu FB. Sugar-sweetened beverages, obesity, type 2 diabetes mellitus, and cardiovascular disease risk. *Circulation*, 2010 Mar; 121(11): 1356–64.
252. Singh GM, Micha R, Khatibzadeh S, Lim S, Ezzati M, Mozaffarian D. Estimated Global, Regional, and National Disease Burdens Related to Sugar-Sweetened Beverage

- Consumption in 2010. *Circulation*, 2015 Aug; 132(8): 639–66.
253. Shi Z, Zhu W, Lei Z, Yan X, Zhang X, Wei S, et al. Intake of Added Sugar from Different Sources and Risk of All-Cause Mortality and Cardiovascular Diseases: The Role of Body Mass Index. *J Nutr* [Internet], 2024; 154(11): 3457–64. Available from: <https://www.sciencedirect.com/science/article/pii/S0022316624010344>
254. Lemmon B, Musicus AA, Grummon AH, Hall MG, Roberto CA, Greenthal E, et al. “High-In” front-of-package labeling of foods high in added sugars, sodium, and saturated fat: A randomized experiment. *Appetite* [Internet], 2026; 216: 108308. Available from: <https://www.sciencedirect.com/science/article/pii/S0195666325004611>
255. Boyland E. Would Reducing Children’s Exposure to Food Advertising Prevent Unhealthy Weight Gain? *Curr Obes Rep*, 2025 Jun; 14(1): 55.
256. Yan RR, Chan CB, Louie JCY. Current WHO recommendation to reduce free sugar intake from all sources to below 10% of daily energy intake for supporting overall health is not well supported by available evidence. *Am J Clin Nutr*, 2022 Jul; 116(1): 15–39.
257. Kelly R, Coro D, Calabro R, Beatty L, Schirmer K. Evaluating campaign concepts aimed at replacing sugar- sweetened beverages with water, 2025; (February 2024): 1–14.
258. Critch JN. School nutrition: Support for providing healthy food and beverage choices in schools. *Paediatr Child Health*, 2020 Feb; 25(1): 33–46.
259. Lima M, Ares G, Deliza R. Comparison of two sugar reduction strategies with children: Case study with grape nectars. *Food Qual Prefer* [Internet], 2019; 71: 163–7. Available from: <https://www.sciencedirect.com/science/article/pii/S0950329318303227>
260. Kolderup A, Svihus B. Fructose Metabolism and Relation to Atherosclerosis , Type 2 Diabetes , and Obesity, 2015; 2015.
261. Santos H, Penha-Silva N. Revisiting the concepts of de novo lipogenesis to understand the conversion of carbohydrates into fats: Stop overvaluing and extrapolating the renowned phrase “fat burns in the flame of carbohydrate.” *Nutrition*, 2024; 130: 112617.
262. Roy P, Kant R, Kaur A, Kumar H, Kumar R. Leptin Resistance and Cardiometabolic Disorders: Bridging Molecular Pathways, Genetic Variants, and Therapeutic Innovation. *Curr Cardiol Rev*, 2025; 21(5): e1573403X356019.
263. Della Corte KA, Bosler T, McClure C, Buyken AE, LeCheminant JD, Schwingshackl L, et al. Dietary Sugar Intake and Incident Type 2 Diabetes Risk: A Systematic Review and Dose-Response Meta-Analysis of Prospective Cohort Studies. *Adv Nutr* [Internet], 2025; 16(5): 100413. Available from: <https://www.sciencedirect.com/science/article/pii/S2161831325000493>

264. Nurkolis F, Harbuwono DS, Astuti N, Sidartawan T. New insight on dietary strategies to increase insulin sensitivity and reduce diabetes prevalence : an expert perspective and recommendation [Internet]. Discover Food. Springer International Publishing; 2025. Available from: <https://doi.org/10.1007/s44187-025-00422-6>
265. Cao X, Wang N, Yang M, Zhang C. Lipid Accumulation and Insulin Resistance: Bridging Metabolic Dysfunction-Associated Fatty Liver Disease and Chronic Kidney Disease. *Int J Mol Sci*, 2025 Jul; 26(14).
266. Lee J, Yun JS, Ko SH. Advanced Glycation End Products and Their Effect on Vascular Complications in Type 2 Diabetes Mellitus. *Nutrients*, 2022 Jul; 14(15).
267. Janzi S, Ramne S, González-padilla E, Johnson L. Associations Between Added Sugar Intake and Risk of Four Different Cardiovascular Diseases in a Swedish Population-Based Prospective Cohort Study, 2020; 7(December).
268. da Silva AA, do Carmo JM, Li X, Wang Z, Mouton AJ, Hall JE. Role of Hyperinsulinemia and Insulin Resistance in Hypertension: Metabolic Syndrome Revisited. *Can J Cardiol*, 2020 May; 36(5): 671–82.
269. Packard CJ, Boren J, Taskinen MR. Causes and Consequences of Hypertriglyceridemia. *Front Endocrinol (Lausanne)*, 2020; 11: 252.
270. Caturano A, Rocco M, Tagliaferri G, Piacevole A, Nilo D, Lorenzo G Di, et al. Oxidative Stress and Cardiovascular Complications in Type 2 Diabetes : From Pathophysiology to Lifestyle Modifications, 2025; 1–28.
271. Klement RJ, Fink MK. Dietary and pharmacological modification of the insulin/IGF-1 system: exploiting the full repertoire against cancer. *Oncogenesis*, 2016 Feb; 5(2): e193.
272. Gallagher EJ, LeRoith D. Obesity and Diabetes: The Increased Risk of Cancer and Cancer-Related Mortality. *Physiol Rev*, 2015 Jul; 95(3): 727–48.
273. Wang M, Xiao Y, Miao J, Zhang X, Liu M, Zhu L, et al. Oxidative Stress and Inflammation : Drivers of Tumorigenesis and Therapeutic Opportunities, 2025; 1–52.
274. Dreher ML. Whole Fruits and Fruit Fiber Emerging Health Effects. *Nutrients*, 2018 Nov; 10(12).
275. Pappé CL, Peters B, Dommisch H, Woelber JP, Pivovarov-Ramich O. Effects of reducing free sugars on 24-hour glucose profiles and glycemic variability in subjects without diabetes. *Front Nutr*, 2023; 10: 1213661.
276. Parajuli J, Prangthip P. Adolescent Nutrition and Health: a Critical Period for Nutritional Intervention to Prevent Long Term Health Consequences. *Curr Nutr Rep*, 2025 Oct; 14(1): 116.